Hemodynamics and outcome of septic shock by Varpula, Marjut
Department of Anaesthesiology and Intensive Care Medicine
Department of Medicine, Division of Emergency Medicine
Helsinki University Central Hospital
University of Helsinki
Helsinki, Finland
HEMODYNAMICS AND  
OUTCOME OF SEPTIC SHOCK
Marjut Varpula
Academic Dissertation
To be presented with the permission of the Medical Faculty of the University of Helsinki,  
for public examination in Auditorium 2 of the Biomedicum, Haartmaninkatu 8.  
On December 8th, 2007, at 10 a.m.
Helsinki 2007
Supervisor
Docent Ville Pettilä
Department of Anaesthesiology and Intensive Care Medicine
Helsinki University Hospital
Helsinki, Finland
Reviewers
Professor Tero Ala-Kokko
Department of Anaesthesiology and Intensive Care Medicine
Oulu University Hospital
Oulu, Finland
Professor Else Tønnesen
Department of Anaesthesia and Intensive Care
Århus University Hospital
Århus, Denmark
Official opponent
Professor Jukka Takala
Department of Anaesthesiology and Intensive Care Medicine
Bern University Hospital
Bern, Switzerland
ISBN 978-952-92-2966-6 (paperback)
ISBN 978-952-10-4347-5 (PDF)
http://ethesis.helsinki.fi
Layout Lifeteam Oy
 
Helsinki University Printing House
Helsinki 2007

4Contents
LIST OF ORIGINAL PUBLICATIONS ........................................................................................6
ABBREVIATIONS......................................................................................................................7
ABSTRACT ...............................................................................................................................9
1 INTRODUCTION ...............................................................................................................10
2 REVIEW OF THE LITERATURE ....................................................................................... 12
2.1 DEFINITIONS OF SEPSIS ........................................................................................... 12
2.1.1 Definitions of septic shock ....................................................................................................... 13
2.2 INCIDENCE OF SEPTIC SHOCK ................................................................................. 14
2.3 HEMODYNAMIC ALTERATIONS IN SEPTIC SHOCK ................................................ 16
2.3.1 Historical perspectives ............................................................................................................... 16
2.3.2 Characteristics  ............................................................................................................................. 16
2.3.3 Vasodilatation  .............................................................................................................................. 16
2.3.4 Myocardial depression  ............................................................................................................. 18
2.3.5 Vascular permeability  ............................................................................................................... 19
2.3.6 Cardiac biomarkers ..................................................................................................................... 20
2.3.7 Microcircular dysfunction ........................................................................................................ 21
2.4 MONITORINg OF HEMODYNAMICS IN SEPTIC SHOCK ......................................... 21
2.4.1 Basic monitoring .......................................................................................................................... 21
2.4.2 Monitoring of global perfusion ............................................................................................. 23
 2.4.2.1 SvO2 ..............................................................................................................................................................................................................................23
 2.4.2.2 ScvO2...........................................................................................................................................................................................................................23
 2.4.2.3 Lactate ........................................................................................................................ 24
2.4.3 Monitoring of regional perfusion ......................................................................................... 25
2.4.4 Role of echocardiography in monitoring  ......................................................................... 25
2.5 TREATMENT OF HEMODYNAMIC ALTERATIONS IN SEPTIC SHOCK ................... 26
2.5.1 Antimicrobial treatment ........................................................................................................... 26
2.5.2 Early Goal Directed Therapy (EGDT) ..................................................................................... 27
2.5.3 Fluids ................................................................................................................................................. 28
2.5.4 Vasopressors  ................................................................................................................................. 29
2.5.5 Inotropic medication .................................................................................................................. 30
2.5.6 Adjuvant therapies ...................................................................................................................... 31
2.6 OUTCOME OF SEPTIC SHOCK .................................................................................. 32
53 AImS OF THE STUDy ..................................................................................................... 34
4 PATIENTS AND mETHODS ............................................................................................. 35
4.1 PATIENTS ................................................................................................................... 35
4.2 STUDY DESIgNS ........................................................................................................ 35
4.3 LABORATORY MEASUREMENTS .............................................................................. 38
4.4 HEMODYNAMIC MONITORINg AND MEASUREMENTS......................................... 38
4.5 INTERVENTIONS  ....................................................................................................... 39
4.6 DATA COLLECTION .................................................................................................... 39
4.7 OUTCOME MEASURES .............................................................................................. 39
4.8 STATISTICAL ANALYSES ............................................................................................ 39
5 ETHICAL ASPECTS.......................................................................................................... 42
6 RESULTS ......................................................................................................................... 43
6.1 PREDICTION OF MORTALITY ACCORDINg TO  
HEMODYNAMIC VARIABLES (I) ...................................................................................... 43
6.2 SVO2 VERSUS SCVO2 IN SEPTIC SHOCK (II) ............................................................ 43
6.3 NT-PROBNP AS A PROgNOSTIC FACTOR IN SEVERE SEPSIS  
AND SEPTIC SHOCK (III) .................................................................................................. 43
6.4 LACTATE AS A PROgNOSTIC FACTOR IN SEPTIC SHOCK (I, III, IV) ..................... 45
6.5 EARLY TREATMENT OF SEPTIC SHOCK IN FINLAND (IV) ..................................... 45
6.6 MORTALITY (I, III–IV) ................................................................................................ 46
7 DISCUSSION ................................................................................................................... 47
8 CONCLUSIONS ............................................................................................................... 52
9 ACKNOWLEDGEmENTS .................................................................................................. 53
10 REFERENCES ................................................................................................................ 55
ORIGINAL PUBLICATIONS ................................................................................................... 66
APPENDIX
6LIST OF ORIgINAL PUBLICATIONS
This thesis is based on the following original publications, which are re-
ferred to in the text by their Roman numerals. The publications are re-
printed with the kind permission of the copyright holders.
I Varpula M, Tallgren M, Saukkonen K, Voipio-Pulkki LM, Pettila V. 
Hemodynamic variables related to outcome in septic shock. Intensive 
Care Medicine 2005; 31: 1066–71.
II Varpula M, Karlsson S, Ruokonen E, Pettila V. Mixed venous oxygen 
saturation cannot be estimated by central venous oxygen saturation in 
septic shock. Intensive Care Medicine 2006; 32: 1336–43.
III Varpula M, Pulkki K, Karlsson S, Ruokonen E, Pettila V, for FINNSEPSIS 
Study Group. Predictive value of N-terminal pro-brain natriuretic 
peptide in severe sepsis and septic shock. Critical Care Medicine 2007; 
35: 1277–83.
IV Varpula M, Karlsson S, Parviainen I, Ruokonen E, Pettila V. 
Community acquired septic shock: Early management and outcome in 
a nationwide study in Finland. Acta Anesthesilogica Scandinavica 2007; 
51:1320–1326.
7ABBREVIATIONS
ACCP American Collage of Chest 
Physicians
ACTH Adrenocorticotropic hormone
APACHE II  Acute Physiology and Chronic 
Health Evaluation II
ARDS  Acute respiratory distress 
syndrome
ATP Adenosine triphosphate
AUC  Area under the curve 
BNP  Brain natriuretic peptide
DO2  Oxygen delivery 
cGMP  Cyclic guanosine 
monophosphate
CVP  Central venous pressure
cTnI  cardiac troponin I
cTnT  cardiac troponin T 
CI Cardiac index 
CO  Cardiac output
CO2 Carbon dioxide
CCO  Continuous cardiac output
Dobu Dobutamine
ED  Emergency department
EF  Ejection fraction
EGDT  Early goal-directed therapy 
ESICM European society of intensive 
care medicine
HES  Hydroxyethylstarch
HR-QoL Health-related quality of life 
ICU  Intensive care unit
IL Interleukin
iNOS  Inducible form of nitric oxide 
synthase
ICD The International Statistical 
Classification of Diseases and 
Related Health Problems 
ISF International Sepsis Forum
KATP  ATP-sensitive potassium 
channels
LA Left Atrium
L/P-ratio lactate/pyryvate ratio
LV  Left ventricle
LVEDP Left ventricular end diastolic 
pressure
LVEF  Left ventricular ejection fraction
MAP Mean arterial pressure
MDS Myocardial depressant 
substance
MMDS Microcirculatory and 
mitochondrial distress 
syndrome
MODS Multiple organ dysfunction 
syndrome
MOF  Multiple organ failure
NEP neutral endopeptidase
NO  Nitric oxide 
NOS Nitric oxide synthase 
NP  Natriuretic peptide
NT-proBNP Amino-terminal pro-brain 
natriuretic peptide 
O2ER  Oxygen extraction ratio 
OPS Orthogonal polarisation spectral 
imaging
PA Pulmonary artery
PAC  Pulmonary artery catheter
PaCO2 Arterial partial pressure of 
carbon dioxide
8Paop  Pulmonary artery occlusion 
pressure
PgCO2 Gastric intramucosal partial 
pressure of carbon dioxide 
PslCO2 Sublingual tissue PCO2 
PVR  Pulmonary vascular resistance 
PEEP  Positive end expiratory pressure
RA Right atrium
rhAPC  Recombinant human activated 
protein C
ROC  Receiver operating characteristic 
curve
RV  Right ventricle
SAFE Saline versus Albumin Fluid 
Evaluation
SaO2  Arterial oxygen saturation
SAPS II  Simplified Acute Physiology 
Score II
SCCM  Society of Critical Care 
Medicine
ScvO2  Central venous oxygen 
saturation
SMR  Standardised mortality ratio
SOAP Sepsis Occurrence in Acutely Ill 
Patients
SPSS Statistical Package for the Social 
Sciences, a computer statistics 
program
SV  Stroke volume
SVC Superior vena cavae
SIRS Systemic inflamma tory 
response syndrome
SOFA  Sequential Organ Failure 
Assessment
SvO2  Mixed venous oxygen saturation
SVR  Systemic vascular resistance 
TNF-α  Tumour necrosis factor-α
VASST Vasopressin and Septic Shock 
Trial 
V1-receptor Vasopressin1-receptor
VO2  Oxygen consumption 
9ABSTRACT
Background Septic shock is the common 
killer in non-coronary intensive care units 
(ICUs). The most crucial issue concerning the 
outcome of septic shock is the early and aggres-
sive start of treatment aimed at normalization 
of hemodynamics and early start of antibiotics 
during the very first hours. The optimal tar-
gets of hemodynamic treatment or impact of 
hemodynamic treatment on survival after that 
are less known.
The objective of this study was to evaluate 
different aspects of the hemodynamic pattern 
in septic shock with special attention to pre-
diction of outcome. In particular components 
of early treatment and monitoring in the ICU 
were assessed.
Patients A total of 410 patients, 218 with 
septic shock and 192 with severe sepsis or 
septic shock were included in the study. The 
patients were treated in several Finnish ICUs 
during 1999–2005. 
Main results In septic shock the most 
important basic hemodynamic variables con-
cerning the outcome were the mean of mean 
arterial pressure (MAP) and lactate during first 
six hours in ICU and the mean MAP, area of 
mixed venous oxygen saturation (SvO2) under 
70  %, and mean central venous pressure (CVP) 
during first 48 hours. The MAP levels under 65 
mmHg and SvO2 below 70  % were the best pre-
dictive thresholds. 
The mean SvO2 was below the mean ScvO2 
during early sepsis. Bias of difference was 4.2  % 
(95  % limits of agreement –8.1  % to 16.5  %) by 
Bland-Altman analysis. The difference between 
saturation values correlated significantly to 
cardiac index (CI) and oxygen delivery (DO2).
The NT-proBNP levels at admission to ICU 
and 72 hours later were significantly higher in 
hospital nonsurvivors. The NT-proBNP values 
72 hrs after inclusion were independent pre-
dictors of hospital mortality. 
The compliance of early treatment accord-
ing to the international guidelines was poor 
in Finnish hospitals and this was reflected in 
mortality. A delayed initiation of antimicrobial 
agents was especially associated with unfavor-
able outcome.
Conclusions This study showed that the 
hemodynamic profile; MAP under 65 mmHg, 
SvO2 under 70  %, and a high CVP may help 
to distinguish patients with an increased risk 
of death in septic shock. NT-proBNP on third 
day may improve the risk assessment further. 
ScvO2 can not be used as a substitute of 
SvO2 in hemodynamic monitoring in ICU. No 
clear evidence, however, of the value of neither 
ScvO2 nor SvO2 as a treatment target in ICUs 
exists.
Early treatment in septic shock is not opti-
mal in Finland. The failure to rapidly diagnose 
and start appropriate treatment increases the 
mortality. With education, local protocol im-
plementation, and follow-up the prognosis in 
septic shock can be improved.
10
1 INTRODUCTION
“Except on few occasions, the patient appears 
to die from the body’s response to infection 
rather than from it.”
Sir William Osler – 1904
The body’s response to an infection is a com-
plex cascade of events that start when patho-
genic micro-organisms activate the expres-
sion of various pro- and anti-inflammatory 
cytokines and apoptotic biomarkers leading 
to humoral, cellular, neuroendocrinological, 
circulatory, and coagulation involvement (Ci-
nel and Dellinger 2007; Annane et al. 2005). 
The first clinical signs of sepsis include the un-
specific symptoms of systemic inflammatory 
response (SIRS); fever, tachycardia, tachypnea, 
or elevation of the peripheral leukocyte count. 
When the host response to sepsis proceeds 
further, the clinical signs of organ failure in-
cluding renal insufficiency, respiratory failure, 
hepatic involvement, septic encephalopathia, 
coagulation abnormalities, and circulatory 
collapse develop. Severe sepsis is characterised 
by concomitant organ dysfunction and septic 
shock results when blood pressures fall despite 
adequate fluid resuscitation.
Severe sepsis and septic shock are leading 
causes of death in non-coronary ICUs in devel-
oped countries (Martin et al. 2003; Sands et al. 
1997). Severe sepsis or septic shock accounts 
for as many deaths as acute myocardial infarc-
tion in hospitals (Angus et al. 2001). In Fin-
land, 11  % of ICU admissions are due to sepsis, 
28  % of these patients die during the hospital 
stay and 40  % within the next year (Karlsson 
et al. 2007). The incidence of severe sepsis and 
septic shock is continuously increasing and al-
though the mortality has decreased during the 
last few decades, the total number of deaths 
is growing (Angus et al. 2001; Friedman et al. 
1998; Martin et al 2003). 
Septic shock is characterised by hemody-
namic disturbances that need correction with 
vasopressor treatment. The typical hemo-
dynamic profile in early sepsis is the periph-
eral vasodilatation, which along with increased 
vessel permeability leads to hypovolemia and 
hypotension. Even after the correction of the 
volemic status, the hypotension persists be-
cause of decreased vascular resistance and dis-
turbances in myocardial contraction. 
The transition from sepsis to septic shock 
may occur fast and the time window for in-
terventions is short. Treatment must promptly 
control the source of infection and restore he-
modynamic homeostasis. Early targeted hemo-
dynamic treatment has improved the outcome 
for severe sepsis (Rivers et al. 2001), while no 
benefit has been observed with the start of he-
modynamic treatment after the development 
of organ failure (Kern et al. 2002). 
A variety of biomarkers have been studied 
for their ability to help in earlier diagnosis, 
treatment decisions, or assessment of prog-
nosis in sepsis. The biomarkers procalcitonin, 
C-reactive protein (CRP), interleukin 6, the 
TREM-1 receptor (triggering receptor ex-
pressed on myeloid cells-1), and lipoprotein 
binding protein may improve early diagnosis of 
a bacterial infection. While natriuretic peptides 
cardiac troponins, neutrophil CD64 expres-
sion, serum interleukin-8 endogenous protein 
C, neopterin, S-100β protein, neuron-specific 
enolase (NSE), plasma DNA, and several other 
cytokines and regulators of inflammation have 
been studied as prognostic indicators (Gibot et 
al. 2004; Meisner 2005; Ngyuen et al. 2006; Li-
vaditi et al. 2006; Rhodes et al. 2006). At pres-
ent their use is limited because of insufficient 
accuracy, prognostic capability, and timeliness. 
Combining information from several markers 
improved diagnostic accuracy for detection of 
the bacterial infection in a recent study (Ko-
foed et al. 2007).
The ultimate target of hemodynamic treat-
ment is the adequacy of oxygen delivery in 
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respect to metabolic needs. The cornerstone of 
hemodynamic treatment is fluid resuscitation. 
The choice of optimum fluid or optimal targets 
of fluid resuscitation, however, are less clear. 
After adequate intravascular volume repletion, 
vasopressor treatment is started for provision 
of sufficient perfusion pressure to organs. Nor-
epinehrine is the drug of choice in septic shock 
but vasopressin has showed promising results 
as an additive agent (Dellinger et al. 2004; 
Farand et al. 2006; Lauzier et al 2006). Myo-
cardial dysfunction is common in septic shock. 
Different guidelines for indications of inotro-
pic support are inadequacy of global perfusion, 
low cardiac output, or severely decreased myo-
cardial function (Dellinger 2003; Dellinger et 
al. 2004). The early treatment protocol in which 
global perfusion was enhanced with red blood 
cells and dobutamine, according to central ve-
nous oxygen saturation (ScvO2) values in the 
emergency department (ED), lead to improved 
survival (Rivers et al 2001). Besides vasoactive 
medications, several other treatment options 
may have an effect on the hemodynamics of 
patients. These include for example low-dose 
steroid treatment, activated protein C, and re-
nal replacement therapy.
The above mentioned landmark study of 
Rivers et al. was one trigger for our study. Riv-
ers’ study showed that the outcome can be im-
proved with a special hemodynamic treatment. 
We wanted to clarify some of the hemody-
namic aspects that are faced in everyday clini-
cal practice in ICUs and in treatment of septic 
patients. Despite several treatment protocols 
that have been introduced, the hemodynamic 
targets had mostly been based on theoreti-
cal backgrounds. We investigated the optimal 
thresholds of commonly used hemodynamic 
variables in respect to the outcome of septic 
shock Because of the increasing interest in the 
use of central venous oxygen saturation instead 
of mixed venous oxygen saturation, we also as-
sessed the correlation and agreement of these 
parameters on reference to the international 
guidelines concerning treatment of septic 
shock . Inspired by the excellent results of early 
goal directed therapy, we wanted to find out 
how the patients with septic shock are treated 
in Finland and how the early treatment af-
fects the outcome. We also hypothesized that a 
simple hemodynamic biomarker, NT-proBNP, 
could be of help in recognizing those prone to 
adverse outcome.
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2.1 DEFINITIONS OF SEPSIS
The current definition of sepsis was produced 
in 1992 by a panel of experts at the Consen-
sus Conference of American Collage of Chest 
Physicians/Society of Critical Care Medicine 
(ACCP/SCCM) (Bone et al. 1992) (Figure1). 
According to these definitions sepsis is the 
state where the patient is having an infection, 
based on clinical or microbiologic findings, 
and signs of systemic inflammation (systemic 
inflammatory response syndrome, SIRS). The 
term “severe sepsis” requires the presence of 
organ dysfunction and septic shock requires 
systemic hypotension refractory to fluid ad-
ministration. 
Current sepsis criteria are shown in table 1.
The introduction of consistent criteria has 
improved the conduct and interpretation of 
clinical trials. Although even after 1992 much 
variation in the selection criteria in studies in 
the field of sepsis has occurred. In some retro-
spective studies ICD-codes from hospital reg-
isters are used instead of the above mentioned 
sepsis criteria, and in some studies a positive 
blood culture (bacteraemia) is required for in-
clusion. Detection of infection has also varied 
from the clinical suspicion to a proven micro-
biological diagnosis.
Current consensus criteria have gained 
much criticism. The SIRS criteria are common 
and unspecific. Actually the outcome of pa-
tients with sepsis (infection and SIRS criteria) 
do not differ from the outcome of patients with 
2 REVIEW OF THE LITERATURE
Figure 1. The interrelationship between systemic inflammatory response syndrome, infection and sepsis. 
Modified from Bone at al 1992.
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infection but not fullfilling the SIRS criteria 
(Alberti et al. 2003). 
In 2001, a consensus conference re-evaluat-
ed the 1992 sepsis definitions. The list of signs 
and symptoms of sepsis were expanded for 
clinical use, but the official definitions of sepsis 
were kept unchanged (Levy et al. 2003). The 
same conference presented a new staging sys-
tem, PIRO, which takes into account four do-
mains: predisposition (P), insult (I), response 
(R), and organ dysfunction (O). The PIRO 
model, however, has so far not gained wide ac-
ceptance in clinical use. 
In 2005, definitions of the common infec-
tions associated with sepsis were described. 
These definitions were made for improving the 
quality and comparability of clinical trials of 
sepsis. Consensus definitions were developed 
for the six most frequent causes of infections 
in septic patients: pneumonia, bloodstream 
infections (including infective endocarditis), 
intravascular catheter-related sepsis, intra-
abdominal infections, urosepsis, and surgical 
wound infections (Calandra et al. 2005).
2.1.1 Definitions of septic shock
In the physiological sense, shock is a medi-
cal condition in which the tissue perfusion 
is insufficient to meet the metabolic demand 
for oxygen and nutrients. In 1992, the ACCP/
SCCM Consensus Conference Committee de-
fined septic shock as follows: “patient is having 
a sepsis-induced hypotension despite adequate 
fluid resuscitation along with the presence of 
perfusion abnormalities that may included, but 
are not limited to, lactic acidosis, oliguria, or 
in acute alteration in mental status” (Bone et 
al. 1992). In clinical practice, however, the con-
nection between infection and hypotension or 
organ failure is not always easy to prove. The 
patient might be hypotensive because of seda-
tion and organ failures might exist because of 
co morbidity. For improving the patient selec-
tion, modified criteria have been used in many 
trials. 
The Prowess criteria, created by Bernand et 
al., define cardiovascular instability as follows: 
systolic blood pressure of 90 mmHg or less or 
Table 1.Definitions and criteria of sepsis (Bone et al. 1992).
Infection Microbial phenomenon characterized by an inflammatory response to the presence of micro-
organisms or the invasion of normally sterile host tissue by those organisms.
Bacteremia The presence of viable bacteria in the blood.
Systemic inflammatory 
response syndrome (SIRS)
The systemic inflammatory response to a variety of severe clinical insults. The response is 
manifested by two or more of the following conditions: 
1. temperature > 38 °C or < 36 °C 
2. heart rate > 90 beats per minute respiratory rate >20 breaths per minute or PaCO2 < 4,3 kPa 
3. white blood cell count > 12  106/mm3 or < 4 000/mm3 or >10  % immature (band) forms
Sepsis The systemic response to infection, manifested by two or more of the SIRS criteria.
Severe sepsis Sepsis associated with organ dysfunction, hypoperfusion or hypotension. Hypoperfusion and 
perfusion abnormalities may include, but are not limited to lactic acidosis, oliguria, or an acute 
alteration in mental status.
Septic shock Sepsis-induced hypotension despite adequate fluid resuscitation along with the presence of 
perfusion abnormalities that may include, but are not limited to, lactic acidosis, oliguria, or an 
acute alteration in mental status. Patients who are receiving inotropic or vasopressor agents 
may not be hypotensive at the time that perfusion abnormalities are measured.
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mean arterial pressure (MAP) of 70 mmHg or 
less for at least 1 hour, despite adequate fluid 
resuscitation, adequate intravascular volume, 
or use of vasopressors (Bernard et al. 2001). 
In a review by Annane et al. the definition of 
septic shock included an even more exact he-
modynamic characterisation with a minimum 
dose of vasopressor needed. According to 
Annanes definition, a patient is having septic 
shock if he or she fulfilled the criteria of severe 
sepsis and has a MAP less than 60 mmHg (less 
than 80 mmHg if previous hypertension) after 
20–30 mL/kg of starch, 40–60 mL/kg of saline 
or pulmonary capillary wedge pressure 12–20 
mmHg. Or patient needs dopamine over 5 μg/
kg/min or norepinephrine or epinephrine a 
maximum of 0.25 μg/kg/min to maintain MAP 
over 60 mmHg (80 mmHg). Refractory septic 
shock was defined as a need for dopamine over 
15 μg/kg/min, norepinephrine or epinephrine 
over 0.25 μg/kg/min (Annane et al. 2005). In 
many trials a predefined minimum needed 
dose of vasopressor treatment has been added 
to the inclusion criteria of septic shock.
An international consensus conference 
about hemodynamic monitoring in shock was 
held in April 2006. One of the recommenda-
tions was that hypotension should not be re-
quired to define shock. Instead, the shock is 
defined as circulatory and cellular dysfunction, 
manifested by markers of hypoperfusion such 
as elevated blood lactate or decreased central 
venous (ScvO2) or mixed venous (SvO2) oxy-
gen saturation with or without hypotension 
(Antonelli et al. 2007).
2.2 INCIDENCE OF SEPTIC SHOCK
The incidence of sepsis has continues to in-
crease in developed countries (Martin et al. 
2003). A study of hospital discharge data in the 
United States from 1979 to 2000 found an in-
crease in incidence from 83 per 100 000 to 240 
per 100 000, about 9  % annually (Martin et al. 
2003). Similarly, in a cohort study conducted 
in 206 French intensive care units (ICUs), 
14.6  % of patients experienced severe sepsis 
or septic shock, compared with 8.4  % of ICU 
patients a decade earlier (Brun-Buisson et al 
2004). Reasons for this constant increasing are 
thought to be the better recognition of sepsis, 
more patients with compromised immune sta-
tus, aged populations, and a growing number 
of resistant microbes. 
The incidence of severe sepsis in epidemio-
logical studies has varied from 0.38 per 1000 to 
3 per 1000 population and from 6.3  % to 27.1  % 
of all ICU admissions. The incidence of critical 
care admissions with severe sepsis has been in-
creasing over time (Brun-Buisson et al. 2004; 
Harrison et al. 2006). The reported incidence 
of septic shock has varied between 7  % to 88  % 
of all sepsis patients and 6.3  % to 14.7  % of all 
ICU admissions (Antonelli et al. 2007). The 
large ranges are not explainable by true differ-
ences, but by a variation in sepsis definitions 
and, for most, the sampling frame in the stud-
ies. The prevalence of cardiovascular dysfunc-
tion (septic shock) in the hospital discharge 
data based study was 7  % of all sepsis patients 
(Martin et al. 2003). In an observational study 
20–27  % of all septic patients in general wards 
and ICUs combined had septic shock, but in 
studies that screened only ICU patients the in-
cidence of septic shock have been up to 88  % 
(table 2). According to a Finnish single centre 
study, severe sepsis or septic shock is more 
common in those ICU patients who have com-
munity acquired infections instead of patients 
with hospital acquired infections on admission 
(Ylipalosaari et al. 2006).
All patient with sepsis are not treated in 
ICUs. In a study regarding emergency depart-
ment visits, most visits for sepsis resulted in 
admission to non-critical units. Only 12  % of 
all sepsis patients were admitted to the ICU 
while the overall hospital admission rate of 
sepsis patients was 87  % (Strehlow et al. 2006). 
In an observational cohort study of severe sep-
sis, based on hospital discharge data, 51  % of 
patients with severe sepsis received intensive 
care (Angus et al. 2001). Sands et al found that 
severe sepsis accounted for 2.0  % of all hospi-
talizations and that 59  % of patients with severe 
sepsis required ICU care (Sands et al. 1997).
Most epidemiological studies have only in-
cluded patients already admitted to the ICUs 
which depends on ICU bed availibility and 
admission policies, effecting the observed in-
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Table 2. The criteria, incidence, and m
ortality of septic shock patients in epidem
iological studies.
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Salvo 1995
Italy
P
C
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criteria
4/1993 – 
3/1994
First 3 cases each 
m
onth in 99 IC
U
s
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106 sepsis, 
severe sepsis or
septic shock
Brun-Buisson 
1995
France
P
C
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1.2.1993
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U
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R
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1995
U
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4/1993
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severe sepsis or
septic shock
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U
SA
P
C
onsensus 
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4/1994
All IC
U
 patients and 
all floor patients w
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blood cultures at 8 
hospitals
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1166 sepsis 
syndrom
e
Angus 2001
U
SA
R
IC
D
-9codes
1995
All cases at all 
hospitals (n = 936) in 
7 U
S states
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192 980 severe 
sepsis
Padkin 2003
U
K
R
"Prow
ess 
criteria"
12/1995–2/2
000
A
ll cases on day 1 in 
91 IC
U
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registry
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sepsis
Teres 2002
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SA
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C
onsensus 
criteria
1998–1999
All cases on day 1 in 
50 IC
U
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sepsis
Alberti 2002
8 countries
P
C
onsensus 
criteria
5/1997 – 
5/1998
All cases in 28 IC
U
s
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3239 sepsis, 
severe sepsis or
septic shock
M
artin 2003
U
SA
R
IC
D
-9 codes
1979–2000
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 subset of all U
S 
hospital adm
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Brun-Buisson 
2004
France
P
C
onsensus 
criteria
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All cases in 206 IC
U
s
3738
546 severe sepsis
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Australia/N
Z
P
C
onsensus 
criteria
5.8.1999
All cases in 23 IC
U
s
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691 severe sepsis
van G
estel 
2004
N
etherlands
P
C
onsensus 
criteria
24h 12/2001
All cases in 47 IC
U
s
455
134 severe sepsis
Flaatten 2004
N
orw
ay
R
IC
D
-10-C
M
 
codes 
1999
All cases in
 all N
orw
egian 
hospitals
700 107
6665 sepsis
Silva 2004
Brazil
P
C
onsensus 
criteria
5/2001 – 
1/2002
All cases in 5 IC
U
s
1383
415 sepsis (214 
severe sepsis)
Karlsson 2007
Finland
P
C
onsensus 
criteria
11/2004 - 
2/2005
All cases in 24 IC
U
s
4500
470 severe sepsis
Vincent 2006
24 European 
countries
P
C
onsensus 
criteria
2w
k 5/2002
All cases in 198 IC
U
s
3174
1177 sepsis
Engel 2007
G
erm
any
P
C
onsensus 
criteria
All cases on one 
day 402 IC
U
s
3877
415 sepsis or sept
shock
H
arrison 2006
U
K
R
"Prow
ess 
criteria"
12/1995- 
1/2005
All cases on one day 
in 172 IC
U
s 
343 860
92 672 severe 
sepsis
*P=prospective, R
= retrospective
%
 of all 
IC
U
 adm
.
P
op. incid. / 1000
H
ospital m
ortality 
(%
)
S
eptic shock %
 
of all sepsis 
cases
H
ospital 
m
ortality of 
septic shock
9.6%
N
A
52.2
21.7
82 %
8.9%
N
A
59
71
N
A
12.6%
N
A
16 sepsis
20 severe sepsis
9
46
N
A
N
A
34 (28-day)
25
N
A
11.2%
3 severe sepsis
28.6
24.4
32.4
27.1%
0.51 severe sepsis 
47.3
88
50.2
11.3%
N
A
36.3
11.3
48
21 %
N
A
13.2–66.8 in subgroups
36
38.8-66.8
N
A
0.83-2.40 sepsis
27.8–17.9
7
N
A
14.6%
N
A
35 (30-d)
56
N
A 
11.8%
0.77
37.5
N
A
N
A
31 %
0.54
N
A
37
N
A
N
A
0.47 severe 
sepsis,1.5 sepsis
27
23.5
29.3
17.4%
N
A
46.9
49
52.2
10.4%
0.38 severe sepsis
28.3
77
38.5
37 %
N
A
32.2
39
54.1
ic 
10.7%
0.76-1.1 severe 
sepsis  
55.2
N
A
62.4
27.0%
0.46-0.66
30.8-34.3
N
A
N
A
16
cidence of severe sepsis and septic shock. Thus, 
in some studies the incidence is not the true 
incidence of severe sepsis or septic shock, but 
the incidence of ICU treated cases of sepsis pa-
tients. The higher incidence of sepsis in ICUs 
may be due to ICU bed shortage when only the 
most critically ill patients are treated in ICU. In 
a prospective, multi-center, observational study 
of ICU treated sepsis in 24 European countries, 
the incidence of severe sepsis of all ICU admis-
sions ranged from 10  % in Switzerland to 64  % 
in Portugal (Vincent et al. 2006). 
The criteria, incidence, and mortality of 
septic shock patients in epidemiological stud-
ies are shown in table 2
2.3 HEmODyNAmIC ALTERATIONS 
IN SEPTIC SHOCK
2.3.1 Historical perspectives
The gram-negative bacteraemia shock syn-
drome was described in 1960 as follows:
‘Before shock became established in the 
patients with bacteraemia the skin was invari-
ably warm and dry, the pulses were full, yet all 
were confused and disorientated ... as shock 
progressed the skin invariably became cold, 
grey and clammy and the pulse rapid, weak, 
and thready’. 
A temporal connection between the ‘warm’ 
and ‘cold’ shock was already understood in 
the 1950´s although the knowledge about 
pathophysiologic mechanisms was lacking. At 
that time the common impression was that hy-
perdynamic warm shock was the initial phase 
of septic shock and hypodynamic cold shock 
was a premorbid phase of shock and mainly 
resulted from myocardial depression. Since 
monitoring techniques with a pulmonary ar-
tery catheter have developed, the understand-
ing about hemodynamics of septic shock has 
increased. During the 1970´s it was generally 
agreed that hypodynamic phase was mostly 
related to inadequate volume resuscitation and 
hypovolemia. 
Although myocardial depression in sepsis 
was incorrectly blamed for the hypodynamic 
phase of shock in 1950`s, in 1984 Parrillo 
and Parker et al. showed, using radionuclide 
cardiac imaging and the pulmonary artery 
thermodilution technique, that left ventricu-
lar ejection fraction (LVEF) is commonly de-
creased in early sepsis despite elevated cardiac 
output (CO). 
2.3.2 Characteristics 
The hemodynamic pattern of septic shock is 
characterized by an early hypercirculatory 
phase with increased CO and decreased sys-
temic vascular resistance (SVR). The clinical 
signs include tachycardia, tachypnea, and warm 
extremities. Vasodilatation and increased per-
meability lead to both absolute and relative hy-
povolemia. Most patients also show some de-
gree of myocardial depression if it is assessed. 
Despite a compensatory increase of CO, the 
elevated SVR, hypovolemia, and myocardial 
depression induce a hypotension, which, by 
definition, is a distinctive mark of septic shock 
(Figure 2). Without aggressive fluid resuscita-
tion in this phase, a profound hypotension 
and progressive acidosis develop leading to 
irreversible shock, multiple organ failure, and 
death. In adequately volume resuscitated pa-
tients during early shock, the global blood flow 
to vital organs (i.e.heart, gut, and kidney) is 
commonly increased, but multiple organ fail-
ure may develop anyway demonstrating that 
the pathophysiology behind organ failure in 
sepsis is much more complex than just circula-
tion (Di Giantomasso et al. 2003). While global 
hemodynamics correlate well to organ hypop-
erfusion in other shock modes, this is not true 
in septic shock. Increasing evidence suggest a 
pivotal role of microcirculation over measur-
able macrocirculation as a cause of organ dys-
function in septic shock and severe sepsis.
2.3.3 Vasodilatation 
The pathological vasodilatation in sepsis is 
due to inappropriate activation of vasodila-
tor mechanisms of smooth muscles and the 
failure of vasoconstrictor mechanisms despite 
an activation of renin-angiotensin-aldosterone 
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system and high plasma concentrations of 
catecholamines. The three main mechanisms 
behind vasodilatation are activation of ATP-
sensitive potassium (KATP) channels in the 
plasma membranes of vascular smooth mus-
cles, activation of the inducible form of nitric 
oxide synthase (iNOS), and deficiency of the 
hormone vasopressin (Landry 2001). 
Several cytokines and endotoxins can in-
duce the expression of iNOS in vascular en-
dothelial and smooth muscle cells resulting 
in a massive release of nitric oxide (NO) and 
profound vasodilatation via cyclic guanosine 
monophosphate (cGMP) lowering intracel-
lular calcium levels. The intracellular calcium 
is eventually responsible for a vasoconstriction 
of the smooth muscle cells. Nitric oxide (NO) 
also decreases the response to catecholamines, 
which may be partly due to activation of KATP 
channels by NO. Besides unwanted effects to 
the vascular system, however, NO has pro- and 
anti inflammatory, as well as oxidant and anti-
oxidant properties, which may have an impor-
tant role in sepsis (Hauser et al. 2005).
The decrease in cellular ATP concentration, 
acidosis, and lactatemia promotes the activa-
tion of KATP channels. Also neurohormonal 
activation, like atrial natriuretic peptide and 
adenosine, which are both increased in septic 
shock (Martin et al. 2000; Witthaut et al. 2003), 
may activate KATP channels. The activation of 
KATP channels produce membrane hyperpo-
larisation of smooth muscles, which closes 
voltage-dependent Ca2+ channels and leads to 
reduction in intracellular Ca2+ and thus to va-
sodilation. 
Vasopressin is a hormone released from 
neurohypophysis. In normal conditions, vaso-
Figure 2. Hemodynamic alterations in early septic shock. Depending on the disease itself, phase of the sepsis, 
and treatments the patient may have features of vasodilatative shock, cardiogenic shock, hypovolemic shock, 
as well as obstructive shock with a rise in pulmonary vascular resistance. Adapted from (Dellinger 2003) with 
permission.
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pressin regulates the water homeostasis of the 
body. In response to hypotension, however, an 
early approximately ten-fold increase in plas-
ma vasopressin occurs and vasopressin con-
tributes to the maintenance of adequate blood 
pressure in early shock. When shock persists, 
the plasma concentrations of vasopressin de-
crease back toward baseline. Inappropriately 
low hormone levels during septic shock may 
be caused by the depletion of neurohypophy-
seal stores or inhibition of synthesis or release 
(Barrett et al. 2007). The vasopressor mecha-
nism of vasopressin is complex. It potentiates 
the vasoconstrictor effect of norepinephrine, 
inactivates KATP channels in smooth muscles, 
decreases the synthesis of iNOS, stimulates 
adrenocorticotropic hormone and hence cor-
tisol secretion, blunts the increase in cGMP in 
cytosol and activate vascular smooth muscle 
V1 receptors (Landry 2001; Barrett et al. 2007). 
Contrary to other vasoconstrictors, vasopres-
sin can also cause vasodilation in some vascu-
lar beds (Okamura et al. 1999), but the signifi-
cance of this in sepsis is not clear.
Chances of cortisol level or vascular re-
sponsiveness to the cortisol are well known in 
sepsis. Glucocorticoids are required for nor-
mal cardiovascular reactivity to angiotensin II, 
epinephrine, and norepinephrine. The effect of 
cortisol on hemodynamics is mediated partly 
by the increased transcription and expression of 
the receptors for these hormones. Cortisol has 
an effect on cardiac contractility, vascular tone, 
and blood pressure. Glucocorticoids are also 
required for the synthesis of N+, K+-ATPase, 
and catecholamines (Marik 2007).
2.3.4 Myocardial depression 
It has been proposed that myocardial depres-
sion contributes to septic shock in at least 50  % 
of the patients (Charpentier et al. 2004; Rabuel 
et al. 2006). Only some of these patients, how-
ever, show inappropriate low oxygen deliv-
ery and thus need an inotropic treatment for 
myocardial depression. In Finnish sepsis study 
(Finnsepsis), 25  % (118 of 470) of patients was 
treated with dobutamine during the first day 
in ICU. Myocardial depression is a reversible 
phenomenon that subsided in 7–10 days if the 
patient survived (Court et al. 2002).
The characteristics of myocardial depression 
in septic shock are reduced ventricular ejection 
fraction and biventricular dilatation, although 
the marked dilatation has not been confirmed 
in some echocardiographic studies (Poelaert 
et al. 1997; Jardin et al. 1999; Charpentier et 
al. 2004). In septic myocardial depression the 
response of left ventricular work to volume 
load is diminished, resulting in a flattened 
Frank-Starling curve (Ognibene et al. 1988). 
Diastolic dysfunction is not as clearly defined, 
but there is evidence from animal and human 
studies that impaired compliance may contrib-
ute to septic myocardial depression (Court et 
al. 2002; Krishnagopalan et al. 2002). Poelart 
et al. demonstrated using tranesophageal 
echocardiography, that cardiac dysfunction in 
septic shock is a continuum from isolated dia-
stolic dysfunction to both diastolic and systolic 
ventricular failure (Poelaert et al. 1997). Right 
ventricular dysfunction closely parallels the 
left ventricular dysfunction in sepsis showing 
a dilatation of the ventricle and a reduced ejec-
tion fraction (EF). 
The evaluation of myocardial function is 
always affected by the loading condition that 
might fluctuate rapidly in sepsis and this has to 
be taken into account when myocardial func-
tion is evaluated. Left ventricular afterload is 
typically very low in early sepsis, unless not af-
fected with vasoactive treatment. Fluid resus-
citation changes the loading condition rapidly 
and a decreased EF might emerge only when 
hypovolemia has been corrected. The right 
ventricle is very vulnerable to an acute increase 
in afterload and severe right ventricular dys-
function or acute cor pulmonale may be pro-
duced by an increase in pulmonary vascular 
resistance (PVR) due to an acute lung injury, 
high PEEP, or high airway pressures during 
ventilator treatment. Hypercapnia or meta-
bolic acidosis may also increase PVR and thus 
contribute to the occurrence of right ventricu-
lar failure in sepsis.
The etiology of myocardial depression 
in sepsis was first thought to be a decreased 
perfusion of the heart. Studies, however, have 
shown that coronary blood flow is normal or 
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even elevated in septic shock (Dhainaut et 
al. 1987). The most important mechanism in 
initiation of myocardial depression is most 
possibly the different circulating myocardial 
depressant substances (MDS) related to the 
pathogenesis of sepsis. The list of all potential 
MDS is extensive, but cytokines, like tumor 
necrosis factor-α (TNF-α) and interleukin-1β 
seem to be of particular importance. The de-
pressant action is mediated at least partly by 
production of NO (Kumar et al. 2001). The 
exact mechanisms behind septic myocardial 
dysfunction are complex, however, and re-
main unclear. The underlying mechanisms 
may include down-regulation of β-adrenergic 
receptors, depressed postreceptor signaling 
pathways, impaired calcium liberation from 
the sarcoplasmic reticulum, impaired electro-
mechanical coupling and mitochondrial dys-
function of the cardiomyocytes (Rudiger and 
Singer 2007).
Besides the septic myocardial depression, 
multiple factors associated with critical illness, 
including hypoxia, acidosis, electrolyte distur-
bances, along with vasoactive medications and 
neurohormonal changes, may affect the cardiac 
function during treatment of septic shock.
The impact of septic myocardial dysfunction 
on the outcome has been controversial. Some 
studies have found an initially lower LVEF 
and more dilated LV in patients who survived 
(Parker et al. 1984; Jardin et al. 1999), while 
some have noticed decreased cardiac function 
in non-survivors (Vincent et al. 1992; Poelaert 
et al. 1997). Different mechanisms in evalua-
tion of cardiac function and fluctuation of the 
loading conditions probably explain these dif-
ferences. In theory, the failure to increase ven-
tricular compliance results in the inability to 
maintain stroke volume and hence cardiac out-
put which explains the better survival of those 
with early LV dilatation (Price et al. 1999). Right 
ventricular dilatation and acute cor pulmonale 
was associated with adverse outcomes in acute 
respiratory distress syndrome (ARDS) (Jardin 
et al. 1994; Jardin and Vieillard-Baron 2007) 
but current treatment guidelines with lower 
tidal volumes and lower inspiratory pressures 
have improved a prognosis of ARDS related 
cor pulmonale (Vieillard-Baron et al. 2001). 
2.3.5 Vascular permeability 
One main problem in septic shock is increased 
vascular permeability (Dellinger 2003). The 
pathophysiology of this, however, is not com-
pletely understood in human septic shock. In 
general the movement of fluids between extra- 
and intravascular compartments depends on 
the hydrostatic, osmotic, and colloid-oncotic 
pressures. In an intact vasculature, the en-
dothelium forms a continuous, semipermeable 
barrier that controls fluid movement between 
intra- and extravascular spaces. The bar-
rier integrity differs between organs and even 
within vascular segments of the same organ. 
Water can diffuse freely through all endothe-
lial pores, and so for example the decrease in 
serum osmolality by the administration of 
hypo-osmolar fluids results in edema forma-
tion. Macromolecules, like albumin, only pass 
through the capillary membrane via larger 
pores that are 10–30×103 times less common 
than small pores. The movement of macro-
molecules through these pores by convection 
depends solely on transcapillary hydrostatic 
pressure and total pore area. Even a minute in-
crease in total area of the large pores may cause 
a substantial loss of macromolecules (Mehta 
and Malik 2006; Stewens et al. 2000).
In sepsis, an inflammatory stimulus leads 
to increased permeability and the loss of bar-
rier function of the endothelium, resulting 
in a shift of water, and macromolecules, and 
proteins into the extravascular space (Holbeck 
2003; Lehr et al. 2000). 
Several plasma mediators, like TNF-α, IL-
1β, IL-6, IL-8, interferon-δ, leptin, comple-
ment and vascular endothelial growth factor 
(VEGF), increase vascular permeability in 
sepsis (Nooteboom et al. 2002, van Eijk et al. 
2006, Pickkers et al. 2005; Dvorak 2006). High 
infusion rates of exogenous catecholamines, 
like norepinephrine, can also induce lung ede-
ma by increasing filtration and micro vascular 
pressure. In theory, the massive fluid loading 
also leads to the increase of hydrostatic pres-
sure and vascular fluid leaks, but on the other 
hand pre-treatment with saline or albumin 
before experimental septic shock reduces 
vascular permeability in rats (Anning et al. 
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2004). Although vascular permeability is not 
a therapeutic target in sepsis, some therapies 
may improve the endothelial barrier function. 
For example simvastatin, sphingosine 1-phos-
phate, adrenomedullin, and activated protein 
C have been studied for this purpose (Looney 
and Matthay 2006; Temmesfeld et al. 2007). 
2.3.6 Cardiac biomarkers
Troponins
Cardiac troponins are intracellular proteins 
that control the calcium-mediated interaction 
of actin and myosin. The troponin complex 
consist of three sub-units: troponin T (cTnT), 
troponin I (cTnI) and troponin C. Cardiac tro-
ponins are not normally detectable in plasma, 
but the elevation of troponin T or troponin I 
is highly sensitive for detecting myocardial cell 
damage. Cardiac troponins are commonly used 
as diagnostic markers in acute coronary syn-
drome, but these can be also elevated in many 
other clinical conditions even in the absence of 
overt ischemia. Elevation of troponins can be 
seen in about half of the patients with severe 
sepsis. In septic shock, a relationship between 
elevated cTnI or cTnT levels and left ventricular 
dysfunction, assessed either by echocardiog-
raphy or a pulmonary artery catheter (PAC), 
have been reported (Favory 2006; Maeder et al. 
2006). The elevation of troponins is associated 
with a poorer prognosis in sepsis.
While coronary circulation is commonly in-
creased in sepsis, several factors may contrib-
ute to the microinjury and minimal myocardial 
cell damage in septic shock. A possible direct 
cardiac myocytotoxic effect of endotoxins, cy-
tokines, or reactive oxygen radicals has been 
postulated. Also microvascular thrombotic 
injury or myocardial ischemia due to sepsis 
induced hypotension, vasopressor agents, ane-
mia or hypoxia may contribute to elevation. 
TnT is also increased in renal failure, which is 
common in septic shock (Favory 2006; Maeder 
et al. 2006).
Natriuretic peptides
Atrial natriuretic peptides (ANP) and brain 
natriuretic peptides (BNP) are polypeptide 
neurohormones, which are produced and se-
creted by cardiomyocytes. Natriuretic peptides 
(NP) induce vasodilatation, increase diuresis, 
and inhibit renin and aldosterone production. 
Thus these hormones are important regulators 
of the fluid and electrolyte homeostasis of the 
body. The NPs may also play a role in inflam-
matory processes, endothelial dysfunction, 
vascular remodelling, counteract the hyper-
trophy and fibrosis of the myocardium, inhibit 
the sympathetic activation and vasopressin 
response, and release of endothelin, cytokines, 
and growth factors (Levin, Gardner and Sam-
son 1998; Ruskoaho 2003; Clerico et al 2006).
The main stimuli for synthesis and release of 
BNP are myocardial wall stress and increased 
intravascular volume. The BNP is mainly pro-
duced in cardiac ventricles but to lesser extend 
also in the atriums. It is secreted into the blood 
as a prohormone, where it is cleaved into ac-
tive BNP and inactive metabolite N-terminal 
pro-brain natriuretic peptide (NT-proBNP). 
The BNP and NT-proBNP are secreted in 
equimolar amounts, but are removed from the 
circulation by different mechanisms, making 
the plasma concentrations unequal (Levin et 
al. 1998; Ruskoaho 2003). Only small amounts 
of BNP are stored in granules and the activa-
tion of the BNP gene is needed for BNP pro-
duction. This activation, however, can occur 
rapidly (Hall 2004).
Renal excretion is regarded as the main 
clearance mechanism of NT-proBNP, whereas 
BNP is cleared by specific clearance recep-
tors and enzyme neutral endopeptidase. 
NT-proBNP has a longer half-life than BNP 
(120 min vs. 22 min)
Both BNP and NT-proBNP are diagnostic 
markers in heart failure and also predictive 
markers of prognosis in several cardiovascular 
diseases (Doust et al. 2004). The use of both 
markers is considered equivalent for diagnosis 
of heart failure (Mueller et al. 2004; Mueller et 
al. 2005) and outcome prediction after myo-
cardial infarction (Richards et al. 2003). They 
are also used in different diagnosis in acute 
dyspnea. These can also be used in follow-up, 
evaluating the adequacy of diuretics and other 
unloading treatment in chronic heart failure 
patients. Synthetic recombinant human BNP 
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(nesiritide) has been approved for the treat-
ment of acutely decompensated congestive 
heart failure. 
In recent years, several studies have found 
elevated levels of NPs in sepsis and evidence 
that NPs could predict mortality in severe sep-
sis and septic shock also exists (Brueckmann et 
al. 2005; Castillo et al. 2004; Charpentier et al. 
2004; Hoffmann et al. 2005; Roch et al. 2005), 
although this is not confirmed in all studies 
(McLean et al. 2007; Rudiger et al. 2006).
The elevation of NPs in sepsis is probably 
multifactorial and there might be variations in 
etiology if BNP or NT-proBNP is used. Eleva-
tion has been associated with septic myocardi-
al depression, assessed with echocardiography 
or a pulmonary artery catheter, and increased 
troponin levels also correlate with elevated NPs 
in sepsis (Charpentier et al. 2004; Brueckmann 
et al. 2005; Hoffmann et al. 2005; Roch et al. 
2005). Other factors, relevant in sepsis, may 
also enhance the production of NPs like IL-1b, 
TNF-α, IL-6, lipopolysaccharides from Gram-
negative bacteria, angiotensin II, endothelin-1, 
α-1-adrenergic stimulation, and hypoxia 
(Clerico et al. 2006; Hanford et al.1994; Harada 
et al 1999; Ma et al. 2005; Tanaka et al. 2004; 
Tomaru et al. 2002). Renal failure seems to in-
crease the level of both BNP and NT-proBNP, 
although the influence on NT-proBNP might 
be more pronounced because of its renal clear-
ance (Jason et al.2005).
2.3.7 Microcircular dysfunction
The microcirculatory unit, which comprised 
of the arteriole, capillary bed, and postcapil-
lary venule, is the final destination from where 
oxygen and nutrients are transported to tissues 
and waste products are removed. Alterations of 
microcirculation in sepsis contribute to the de-
velopment of MODS (Vincent and De Backer 
2005). In sepsis, several derangements in mi-
crocirculation have been reported: reduction 
of the number of perfused capillaries, reduced 
red blood cell deformability, endothelian cell 
dysfunction with increased permeability and 
apoptosis, altered vasomotor tone, an increased 
number of activated neutrophils, and activa-
tion of the clotting cascade with fibrin deposi-
tion (Vincent and De Backer 2005). These mi-
crocirculatory derangements can occur despite 
preserved arterial pressure and on the other 
hand the treatment with vasoactive medica-
tion for preserving MAP may indeed decrease 
the microvascular blood flow despite increase 
in perfusion pressure (Krejci et al. 2006, Hil-
tebrand et al. 2007). In an experimental study 
with a fecal peritonitis model, administration 
of norepinephrine, epinephrine, or phenyleph-
rine increased perfusion pressure, but both 
norepinephrine and epinephrine decreased 
microcirculatory flow in the intestine while 
phenylephrine had no effect on regional blood 
flow (Krejci et al. 2006). Both experimental 
and human studies have shown that microvas-
cular alterations associate with poor outcome 
in sepsis (Sakr et al. 2004, Trzeciak et al. 2007). 
Microcirculation and its role as a therapeutic 
target are under wide investigation in septic 
shock. Vasodilatators, like prostacyclin and ni-
troglycerine or other NO donors, have showed 
promising results for the improvement of mi-
crocirculatory perfusion in sepsis (Siegemund 
et al. 2007; Spronk et al. 2002)
Besides impaired microcirculation, sep-
tic shock may also induce changes in oxygen 
utilisation at a mitochondrial level leading to 
“cytopathic hypoxia” or “microcirculatory and 
mitochondria distress syndrome” (MMDS) 
(Spronk et al. 2005).
2.4 mONITORING OF 
HEmODyNAmICS IN SEPTIC SHOCK
“Not everything that counts can be counted, 
and not everything that can be counted 
counts.”
Albert Einstein
2.4.1 Basic monitoring
Monitoring of the hemodynamics should be 
a diagnostic aid that helps in treatment deci-
sions. The ultimate purpose of hemodynamic 
monitoring in septic shock is to determine if 
the circulation is consistent with the metabolic 
needs of the tissues, and to determine which 
22
components of the hemodynamic profile need 
to be adjusted for adequate consumption-de-
mand balance for avoiding, or correcting, tissue 
hypoxia. Although hemodynamic monitoring 
is considered essential in circulatory shock, its 
targets and benefit are poorly documented. 
With standard monitoring techniques it is 
not possible to reliably assess tissue hypoxia 
and thus monitoring of optimal consumption-
demand balance is always somewhat extrapo-
lative. Clinical, as well as laboratory signs of 
hypoperfusion, have to be taken into account 
together with hemodynamic monitoring in 
the treatment of the patient. The fact that the 
pathophysiology of tissue hypoxia is more 
complex than just the derangements in circu-
lation must be remembered.
For the last four decades, the pulmonary ar-
tery catheter (PAC) has been used for hemody-
namic monitoring of critically ill. The benefits 
of PAC have been questioned in recent years. 
Three recent studies and two meta-analysis 
showed that the complication or mortality rates 
are not increased with PAC, although no ben-
efit could be shown either (Rhodes et al. 2002; 
Richard et al. 2003; Shah et al. 2005; Harvey et 
al. 2005; Harvey et al. 2006). Richard et al. con-
ducted a multicenter randomised controlled 
study on the effects of PAC on the outcome in 
patients with shock or ARDS. In 676 patient, 
from which 452 had septic shock, morbidity or 
mortality benefits could not be observed, but 
the authors concluded that the PAC remains a 
safe procedure for the management of patients 
with shock or ARDS. It has since been argued 
that the lack of the benefit in those studies 
could be caused by their lack of goal-oriented 
treatment protocol. It is also unclear as to what 
the real differences between the monitoring of 
the patients was, because some of the patients 
had some alternative method of cardiac out-
put monitoring and some had a PAC without 
a continuous SvO2 measurement. In the study 
of Richard et al., 64  % in the PAC group and 
78  % in the control group had echocardiogra-
phy performed for the assessment of hemody-
namics. Actually, so far no study demonstrated 
that any other monitoring techniques could 
improve the outcome of the patients.
Mean arterial pressure (MAP) is the driv-
ing perfusion pressure of the tissues. MAP is 
commonly monitored invasively and continu-
ously via the radial or femoral artery. Oscil-
lometric blood pressure measurement is not a 
reliable substitute for intra-arterial blood pres-
sure measurement in a critically ill patient 
(Cohn 1967; Bur et al. 2003). 
Central venous pressure (CVP) reflects the 
right atrial pressure and is commonly used as 
a marker of preload. It can be measured with a 
CVP- catheter or with PAC.
Pulmonary artery occlusion pressure 
(Paop), or wedge pressure, is measured with 
PAC while the balloon on the distal tip located 
in a West zone 3 in the lungs is inflated, i.e. 
wedged. In the West zone 3 the pulmonary ar-
terial and venous pressure exceed the alveolar 
pressure, so the wedged balloon measure the 
backpressure of left atrium. West zone 3 condi-
tions exist at the bottom region of the lungs. 
Paop is thought to be a reflection of the left ven-
tricular end-diastolic pressure (LVEDP) and it 
is commonly used as a preload measurement. 
Several studies, however, have shown that CVP 
or Paop are not reliable methods to assess the 
patients’ ability to increase the cardiac output 
for a fluid challenge (Tavernier et al. 1998; Mi-
chard et al. 2000; Kumar et al. 2004).
The cardiac output, cardiac index and 
stroke volume (CO, CI, SV) can be measured 
with a thermodilution method with PAC. In 
that method the fixed volume of cool fluid is 
injected through a proximal port of the PAC 
and the change of temperature is registered 
by a thermometer at the tip of PAC. The CO 
is calculated using temperature-time decay 
curves by Stewart-Hamilton equation. Cardiac 
output can be measured continuously (CCO) 
with special PAC catheters with a thermofila-
ment.
Cardiac output can also be assessed with 
echocardiography using doppler techniques, 
pulse contour analyses from the arterial pres-
sure waveform of a peripheral artery, esopha-
geal doppler, transpulmonary thermodilution, 
thoracic electrical bioimpedance, or partial 
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CO2 rebreathing technique based on the in-
direct Fick method. Different techniques have 
mostly been compared in patients without 
shock. Although the mean bias have been clini-
cally acceptable, the deviations have been wide 
in some studies. Continuous and automatic 
monitoring are advantages of the new meth-
ods. The measurement of CO or targeting to 
some predefined CO, however, have not shown 
any impact on outcome in septic shock. 
2.4.2 Monitoring of global perfusion
2.4.2.1 SvO2
Mixed venous (SvO2) saturation reflects the 
balance between oxygen requirement and oxy-
gen delivery, and thus may be used to assess 
the adequacy of tissue oxygenation. 
Oxygen delivery (DO2) depends on hemo-
globin concentration, cardiac output, and ar-
terial oxygenation (DO2  =  CO  ×  Hb  ×  1.31  × 
SaO2    +  (0.003  ×  PaO2)) In normal conditions 
only about 25  % of arterial oxygen are used for 
metabolic needs and thus the normal SvO2 is 
about 75  %. If DO2 falls relative to oxygen con-
sumption (VO2) or oxygen demand increase, 
the tissues begin to extract more oxygen 
(oxygen extraction ratio, O2ER  =  VO2 / DO2) 
and SvO2 falls. When the mismatch between 
DO2 and VO2 can not be compensated by an 
increased O2ER, anaerobic metabolism and 
lactic acidosis occur. It have to be remem-
bered, however, that SvO2 is a flow-weighted 
average of venous oxygen content of all differ-
ent organs, and thus may not accurately reflect 
tissue hypoxia of an individual organ (Huang 
2005).
The SvO2 is measured from the pulmonary 
artery blood samples obtained from a PAC dis-
tal port. By using infrared oximetry, which is 
based on reflection spectrophotometry, SvO2 
can be monitored continuously. SvO2 predicts 
mortality in sepsis (Heiselman et al.1986; Krafft 
et al. 1993), but no clear evidence of its value 
as a treatment target is available. Maintaining 
SvO2 ≥ 70  % failed to improve the outcome in a 
large study of intensive care unit patients (Gat-
tinoni et al. 1995). 
2.4.2.2 ScvO2
Central venous oxygen saturation (ScvO2) is a 
mixture of venous blood from the upper body, 
while SvO2 reflects the flow-weighted oxygen 
balance of the whole body. The ScvO2 reflects 
changes in oxygen delivery, or changes in con-
sumption in the upper body and brain. ScvO2 
is measured in blood samples taken from cen-
tral venous catheter or continuously by using 
a fiberoptic central venous line. The sampling 
site is important for the right interpretation of 
values, because saturation values are different 
in the right atrium, in the inferior vena cava, 
and in the superior vena cava when blood from 
the lower body and coronary sinus has been 
mixed (Lee et al 1972; Edwards and Mayall 
1998). 
Normally ScvO2 is lower than SvO2, but for 
patients in shock a consistent reversal of this 
relationship occurs and ScvO2 may overesti-
mate the true SvO2 under shock conditions. In-
dividual values in shock may differ up to 18  % 
to 22  % (Lee et al. 1972; Faber 1995; Edwards 
and Mayall 1998; Turnaoglu et al. 2001; Rein-
hart et al. 2004). The reason for this difference 
is understood when considering that SvO2 is a 
mixture of saturation of the superior vena cava 
(ScvO2), the inferior vena cava, and the coro-
nary sinus, which are all blended according to 
the proportion of blood flow. The distribution 
of blood flow in a low-flow condition away 
from renal, splanchnic, and mesenteric circu-
lation toward cerebral and myocardial perfu-
sions, including a more desaturated blood 
from the coronary sinus and less well saturated 
blood from renal circulation, contribute to this 
difference. During sedation decreased oxygen 
consumption by brain and hypoperfusion 
within the hepatosplanchnic region leading to 
a highly depressed hepatic and splanchnic ve-
nous saturation may also explain the difference 
between ScvO2 and SvO2.
Early goal-directed therapy (EGDT), aimed 
at a ScvO2 over 70  % during the first six hours, 
has been shown to reduce mortality among 
patients with severe sepsis and septic shock 
(Rivers et al. 2001). The use of ScvO2 in ini-
tial resuscitation has been applied to the sepsis 
guidelines (Dellinger et al. 2004). ScvO2, like 
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SvO2, is an excellent measurement in detecting 
decreased DO2. ScvO2 reflects hypovolemia 
and acute cardiac failure more accurately than 
conventional hemodynamic measurements 
(Goldman et al. 1968; Ander et al. 1998; Mad-
sen et al.1993; Rady et al. 1992; Scalea et al. 
1990). After a resuscitation period, however, 
ScvO2 is mostly normal (Reinhart et al. 2004). 
At the time of unplanned admission to a mul-
tidisciplinary ICU about 20  % of patients have 
a ScvO2 below 60  % and these patients have a 
higher mortality than patients with a higher 
ScvO2 (Bracht et al. 2007).
2.4.2.3 Lactate
When oxygen delivery fails to meet tissue 
oxygen demand a compensatory increase in 
oxygen extraction occurs. If this compensatory 
response is exhausted, tissue hypoxia leads to 
anaerobic metabolism, and lactate production 
as the end product of anaerobic glycolysis. 
Under basal conditions about 0.8–1.0 
mmol/kg/h lactate is produced continuously 
mainly by the skeletal muscle, skin, brain, red 
blood cells, intestine, and renal medulla. This 
lactate is utilized predominantly by the liver 
(Cori cycle), kidneys and heart muscle. Lactate 
clearance rate may exceed a level of 320mmol/
L/h. If the production exceeds the clearance 
capability, hyperlactatemia will develop.
In the normal situation glucose is metabo-
lised mainly via an aerobic pathway, in which 
pyryvate enters into tricarboxylic acid cycle 
(krebs cycle). Energy production of this aero-
bic metabolism is 36 ATP molecules. If pyry-
vate molecule is metabolized to lactate only 
2 ATP molecules is yielded (Figure 3) (Fall 
and Szerlip 2005; Levy 2006). The important 
reason for lactatemia in septic shock is the hy-
poperfusion and lactate represent a useful and 
clinically obtainable surrogate marker of tissue 
hypoxia. Other explanations also exist, how-
ever, for the high lactate values in sepsis. Pyru-
vate dehydrogenase dysfunction or exhaustion, 
liver failure, use of epinephrine, and increased 
protein catabolism may increase lactate in sep-
sis. Actually, the hyperlactatemia in sepsis is 
not necessarily associated with the elevation of 
the lactate to pyruvate ratio (L/P ratio), which 
also suggests other mechanism than hypoper-
fusion alone behind lactatemia (Suistomaa et 
al. 2000). Recent studies have speculated that 
the increased lactate production, mostly by 
muscles could be beneficial extra fuel for or-
gans in sepsis (Levy 2006).
Whatever the reason, hyperlactataemia re-
mains an excellent prognostic marker in sepsis. 
The initial lactate level, peak lactate level, dura-
tion of lactatemia, and lactate clearance during 
the first six hours have been shown to predict 
survival in sepsis (Bakker et al. 1991; Nguyen 
et al. 2004). 
A venous lactate level greater than 4 mmol/l, 
measured in the emergency department (ED), 
is highly specific for recognition of poor hos-
pital outcome of patients with signs and symp-
toms suggestive to infection (Shapiro et al. 
2005;Tretzjak et al.2007). 
Septic patients with preserved autonomic 
compensatory responses, like young people, 
may have elevated lactate levels as a sign of 
global tissue hypoperfusion despite stable he-
modynamic parameters. The outcome of these 
patients, without proper therapy, might be even 
worse than of those with clinical shock. In a 
subgroup analysis from the Rivers et al. pivotal 
EGDT study, patients with a raised lactate but 
normal blood pressure in the standard therapy 
group had a 60-day mortality of almost 70  % 
while it was 46.5  % for the whole standard 
therapy group (Bennet 2005; Trzeciak and Riv-
ers 2005).
Figure 3. A simplified chart of glycolysis
Cytosol
Glucose
Cori cycle
Pyryvate Lactate + 2 ATP
Acetyl-CoA
Mitochondria
Krebs cycle
CO2 + H2O + 36 ATP
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2.4.3 Monitoring of regional perfusion
Blood flow in a single organ may be severely 
impaired despite sufficient global hemody-
namic parameters (Ruokonen et al. 1993). 
Insufficient hepatosplanchnic blood flow may 
contribute to the pathogenesis of multiple 
organ dysfunction (Ackland et al.2000). Im-
paired microcirculation is associated to mor-
tality in sepsis (Sakr et al. 2004; Trzeciak et al. 
2007). Poeze et al. showed that after a resusci-
tation period of sepsis, regional variables, like 
gastric mucosal pH, mucosal PCO2 gap, and 
indocyanine green blood clearance were better 
outcome predictors than global hemodynamic 
variables (Poeze et al. 2005). 
The methods for measuring regional or-
gan perfusion or microcirculation have been 
under wide investigation. Gastric tonometry 
is a method for providing information about 
the circulation of the stomach and the rest of 
the splanchnic bed. The monitoring of gas-
tric intramucosal pH (pHi) was initially used 
to assess dysoxia. The calculation of the pHi, 
however, involves a number of uncertainties 
and instead of pHi the PCO2 gap, defined as a 
difference between the gastric mucosal PCO2 
and the arterial PCO2 (PgCO2), may more spe-
cifically reflect the adequacy of gastric mucosal 
blood flow.
Several studies have demonstrated the 
prognostic value of gastric tonometry in septic 
shock (Maynard et al. 1993; Poeze et al. 2005), 
but the treatment aimed at increasing pHi has 
not improved outcome in trials (Gomersall et 
al. 2000). Evidence also exists that gastric PCO2 
is not a reliable marker of hepatosplanchnic 
perfusion in sepsis (Creteur et al.1999). The re-
liability of measurements are prone to a num-
ber of technical limitations. In clinical use the 
enteral feeding and gastric ulcer profylaxis may 
have an effect on the values of gastric tonom-
etry (Creteur 2006). Sublingual capnometry 
is a simple, noninvasive method for the as-
sessment of increased sublingual CO2 tension, 
although a commercially available sublingual 
capnometry device is currently lacking. Sub-
lingual PCO2 (PslCO2) correlates with gastric 
tonometry (Creteur 2006; Creteur et al. 2006) 
and it was a better predictor of outcome than 
traditional markers of tissue hypoxia, like lac-
tate and SvO2 in 54 hemodynamically unstable 
critically ill patients (21 with septic shock) 
(Marik and Bankov 2003).
Orthogonal polarisation spectral imaging 
(OPS) is a new technique for imaging micro-
circulation in clinical studies. The improve-
ment of microcirculatory alterations, assessed 
sublingually with an OPS, predict survival in 
septic shock while persistent microcirculatory 
alterations are associated with multiple organ 
failure (MOF) and death (Sakr et al. 2004).
Several techniques for monitoring the re-
gional perfusion and microcirculation have 
been used in experimental settings, but no 
clinically useful and reliable methods are avail-
able. In addition, regional perfusion measure-
ments have not showed outcome benefit as an 
endpoint to guide the therapy. Routine assess-
ment of regional perfusion or microcirculation 
is not yet recommended for shock (Antonelli 
et al. 2007). 
2.4.4 Role of echocardiography  
in monitoring 
The use of echocardiography in the monitoring 
of critically ill patients has increased during 
the last few years. It provides a real-time two-
dimensional structural and functional imaging 
of the heart, along with doppler techniques 
making it possible to assess data on dynamic 
circulation, loading conditions, and cardiac 
output.
In septic shock echocardiography may give 
additional information to the conventional 
monitoring of the volemic status, systolic or 
diastolic dysfunction of the left ventricle, right 
heart failure, and fluid-responsiveness. With 
echocardiography it is possible to rule out 
some structural problems like pericarditis or 
endocarditis, which may be present in sepsis. 
It is also possible to follow the short-term in-
fluence of the hemodynamic treatment on 
cardiac function (Barbier et al. 2004; Jardin 
and Vieillard-Baron 2005; Jardin et al. 1999; 
Vieillard-Baron et al. 2004)
Echocardiography is not a continuous mon-
itoring method and the use of that requires a 
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high degree of user expertize. Echocardiogra-
phy based monitoring has not been studied in 
goal oriented trials and its benefit over some 
other monitoring techniques has not been as-
sessed. An example of echocardiography based 
monitoring strategy in septic shock is shown 
in Figure 4.
2.5 TREATmENT OF HEmODyNAmIC 
ALTERATIONS IN SEPTIC SHOCK
2.5.1 Antimicrobial treatment
The cornerstone of the treatment of septic 
shock is the early and adequate eradication 
of infection with antimicrobial agents or sur-
gical source control. The antibiotic treatment 
can also be seen as a part of the hemodynamic 
treatment. The animal data has shown that in 
early septic shock both antibiotics and cardio-
vascular support alone are relatively ineffective 
in the treatment. When combined, however, 
these two therapies provide a significantly bet-
ter chance of survival (Natanson et al 1990). 
In an animal model of sepsis, a critical time 
point for first the antibiotic dose, concern-
ing outcome, seems to be the onset of clinical 
shock (Kumar et al 2006). In a murine model 
of Escherichia coli septic shock, a persistent 
increase of serum lactate, TNF- alpha, IL-6 
levels, and remarkably increased mortality 
was found, if antibiotic treatment was initiated 
more than 12 hours after implantation of a bac-
teremic clot when clinical signs of shock had 
already developed (Kumar et al 2006). Kumar 
et al. also showed that the timing of antibiotic 
treatment is relevant even after symptoms of 
clinical shock have developed. In a retrospec-
tive analysis of over 2500 patients with septic 
shock, the mortality increased for every single 
hour that the adequate antimicrobial treatment 
was delayed after the beginning of hypotension 
(Kumar et al 2006). 
Antimicrobial agents may also have other 
effects than antimicrobe eradication. Azole 
antifungal agents have been shown to interfere 
with neutrophils and lymphocyte function and 
Figure 4. An example of echocardiography guided hemodynamic monitoring and treatment of septic shock. 
Adopted from (http://www.pifo.uvsq.fr/hebergement/webrea/index.php?option=com_content&task=view&id=1
4&Itemid=66) with permission. 
SVC Superior Vena Cava, LVEF Left ventricular ejection fraction, NEP Norepinephrine.
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ketoconazole may inhibit thromboxane A2 
synthetase, which have a direct role in cardio-
pulmonary dysfunction and pulmonary edema 
in sepsis. Intravenous fluconazole reduced the 
development of organ failure and mortality in 
intra-abdominal sepsis in small prospective 
placebo-controlled trial (Jacobs et al. 2003)
2.5.2 Early Goal Directed Therapy (EGDT)
In 2001, Rivers et al. published a study about 
Early Goal Directed Therapy (EGDT) in se-
vere sepsis. In that study the early recognition 
and early aggressive treatment starting already 
in the ED, showed a 16  % absolute mortal-
ity reduction compared to more conservative 
treatment. Thereafter, the concept of EGDT 
has been accepted into sepsis treatment guide-
lines. 
The protocol of the EGDT study is shown 
in Figure 5. The main differences between the 
EGDT and standard group in that study were 
the amount of fluids, inotropes, and red blood 
cell transfusions during the first six hours 
of treatment. After three days, however, the 
amount of fluids and inotropes did not differed 
between the groups. The most important issue 
in the EGDT concept was the earlier timing 
of the aggressive treatment. A recent analysis 
shows that early hemodynamic optimisation 
decreases several biomarkers in septic shock 
and this decrease is associated with the sever-
ity of global tissue hypoxia. Significant de-
crease with EGDT therapy can be seen as soon 
as three hours after the start of treatment for 
interleukin-1 receptor antagonist (IL-1ra) and 
intercellular adhesion molecule-1 (ICAM-1), 
after six hours for tumor necrosis factor-α 
(TNF-α) and caspase-3, and after 12 hours for 
interleukin-8 (IL-8) (Rivers et al. 2007).
The EGDT study was the first ever to show 
a mortality reduction with a specific hemody-
namic treatment in septic shock. Earlier studies, 
which have targeted supranormal oxygen deliv-
ery, had showed inconsistent results in critically 
ill, mostly postoperative patients. The concept 
of supranormal oxygen delivery was originally 
based on observational studies of critically ill 
patients, which have showed this kind of hemo-
dynamic pattern in survivors vs. nonsurvivors. 
The meta-analysis of the studies on goal di-
rected hemodynamic optimisation in high-risk 
patients, however, showed that actually the only 
important issue concerning mortality in these 
had been the timing. If the treatment had been 
Figure 5. EGDT protocol. Modified from (Rivers et al. 2001).
Suspected severe sepsis or 
septic shock
Antibiotic administration as 
early as possible + source 
control
Initial 20 ml/kg crystalloids 
or colloid equivalent
CVP < 8 mmHg
MAP < 65 mmHg
ScvO2 < 70 %
> 8–12 mmHg
> 65 to < 90 mmHg
> 70 %
Goal
Fluid Therapy
Vasopressors
Packed red blood
cell to Hct > 30  %
Inotropes if ScvO2
remains < 70 %
after transfucion
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started before development of organ failure, the 
mortality was reduced with goal directed treat-
ment (Kern and Shoemaker 2002). 
The EGDT protocol has been widely ad-
opted and several reports have reported the 
reduced mortality in individual hospitals after 
implementation of EGDT in clinical reality 
(Sebat et al. 2005; Gao et al. 2005; Kortgen et al. 
2006; Micek et al. 2006; Nguyen et al. 2006; Ot-
ero et al. 2006; Shapiro et al. 2006; Trzeciak and 
Rivers 2003). Nguyen et al reported that even 
after the active implementation process only a 
minority of patients is treated exactly accord-
ing to the guidelines, however, but those who 
are most actively treated have a better outcome 
(Nguyen et al. 2007).
2.5.3 Fluids
Target of treatment
The vasodilatation in the early phase of the 
septic shock along with the disturbances in 
vessel permeability lead to hypovolemia, which 
always needs a rapid correction with volume 
resuscitation. Although the fluid therapy in 
early sepsis is a necessity, the optimum target 
in monitoring and the choice of the fluid are 
less clear. 
The theoretical target of volume expansion 
is the increase in cardiac output and hence the 
global perfusion. The minimum goal in fluid 
resuscitation according to the EGDT study 
(Rivers et al 2001) and the Surviving Sepsis 
guidelines (Dellinger et al. 2004) is CVP over 8 
mmHg or over 12 mmHg in mechanically ven-
tilated patients. Some reviews have suggested 
a left heart filling pressure of 8–12 mmHg 
or 12–15 mmHg (Hollenberg et al. 2004; 
Ruokonen et al. 2002; Zanotti et al. 2006), 
based on an older small study by Packman et 
al. in whick the fluid resuscitation over this 
point did not result in a further increase in SV 
or CI (Packman et al. 1983). Plenty of evidence 
exists, however, that CVP or Paop are poor in-
dicators of preload (Kumar et al. 2004; Magder 
2005; Osman et al. 2007) and several factors, 
like elevated intrathoracic pressure or intra-
abdominal pressure, hamper the interpretation 
of intrathoracic pressure measurements. Also 
it is noteworthy, that preload as such, does not 
correspond to a patient’s ability to increase 
cardiac output with a fluid challenge, to fluid 
responsiveness (Kumar et al. 2004; Michard et 
al. 2000; Tavernier et al. 1998). 
According to the Frank-Starling curve, 
the relationship between preload and cardiac 
output is not linear and the response to the 
volume expansion is seen only in the steep 
part of the pressure-volume curve. In the flat-
ter part of curve the volume expansion will 
not increase the stroke volume and the overt 
fluid therapy may only lead to adverse effects, 
like lung edema, tissue edema, elevated intra-
abdominal pressure, hyperchloremic acidosis 
(Scheingraber et al. 1999), dilutional anemia, 
and eventually to decreased perfusion and 
even to increased mortality. Positive fluid bal-
ance was an independent predictor of mor-
tality in the large observational SOAP study 
(The Sepsis Occurrence in Acutely Ill Patients) 
(Vincent et al. 2006). The conservative strategy 
of fluid management improved lung function 
and shortened the duration of mechanical 
ventilation and intensive care of patient with 
acute lung injury in a randomised study (Wie-
demann et al. 2006).
The assessment of fluid responsiveness may 
help with the achievement of optimal volume 
status. The fluid responsiveness can be assessed 
with several dynamic measures based on intra-
pleural pressure swings during ventilation. For 
example systolic pressure variation, pulse pres-
sure variation, a decrease in systolic pressure 
from baseline (dDown), stroke volume varia-
tion, changes in aortic blood flow velocity, and 
aortic velocity-time integral seen with a pulse-
doppler echocardiography, and collapsibility 
of the superior or inferior vena cava seen with 
echocardiography have been introduced for 
this purpose (Preisman et al. 2005; Kramer et 
al. 2004; Tavernier et al. 1998; Reuter et al. 2003; 
Slama et al. 2004; Slama et al. 2002; Feissel et al. 
2001; Vieillard-Baron et al. 2004; Barbier et al. 
2004; Feissel et al. 2004). The hemodynamic 
response to passive lag raising also predicts the 
patient fluid responsiveness (Lafanechere et al. 
2006, Monnet et al. 2006). Several limitations 
in dynamic measurements also exists and rou-
tine use of these is not recommended in shock 
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although some selected patients may have an 
advantage with these (Antonelli et al. 2007).
Volume treatment in early septic shock is 
mandatory, but it has to be individually tapered 
and carefully monitored with the clear targets 
to increase the global or regional perfusion.
Choice of fluid
According to the recent guidelines both col-
loids and crystalloid are equally suggested for 
volume resuscitation in sepsis (Vincent and 
Gerlach 2004) based mostly on the meta-
analyses and systematic reviews concerning 
patient with critical illness in general, mostly 
surgical or non-septic. Results of these studies 
can not be directly extrapolated to the patients 
with sepsis and even septic patients may need 
different consideration in volume replacement 
therapy in early and later phases of sepsis.
Colloids and crystalloids have several dif-
ferent properties, which may have an influence 
on the course of sepsis. The similar elevation 
of filling pressures can be achieved with both 
types of fluid but approximately three to four 
times more volume of crystalloid than colloid 
is required for this and this is accompanied 
with a higher incidence of pulmonary edema 
(Rackow et al. 1983). In an experimental study, 
early volume resuscitation with albumin and 
HES resulted in higher CO and DO2 and lower 
lactate levels than gelatin or Ringer’s lactate in 
septic shock, but the choice of fluid did not af-
fect the outcome (Su et al. 2007). It seems that 
hydroxyethylstarch (HES) administration, at 
least 10  % HES 200/0.5 and 6  % HES 200/0.6–
0.66, may be a risk factor for acute renal failure 
in patients with severe sepsis or septic shock 
(Schortgen et al. 2001; VISEP trial, prelimi-
nary data). But other synthetic colloids may 
also have adverse effects to renal function (Da-
vidson 2006). Use of colloids can decrease the 
platelet aggregation and modify the inflamma-
tion but whether this is unfavourable in sepsis 
is not known. The choice of a specific fluid may 
influence to the development of intra-abdom-
inal hypertension or cerebral edema (O’Mara 
et al. 2005). Controlled studies on these issues 
in sepsis are lacking, however, and the contri-
bution of these characteristics on mortality is 
unresolved.
The use of albumin in volume resuscitation 
was studied in the large SAFE study (Saline 
versus Albumin Fluid Evaluation) with almost 
7000 critically ill patients. Although no signifi-
cant difference in mortality in the whole study 
group could be detected, a non-significant 
trend to better survival was observed in a non-
randomised subgroup of over 1200 patients 
with severe sepsis (Finfer et al. 2004). System-
atic reviews and meta-analyses have come to 
different conclusions concerning the safety or 
advantages of the use of albumin in critically ill 
patients and so far its use is not recommend-
ed for volume resuscitation of septic patient 
(Anonymous 1998; Wilkes and Navickis 2001; 
Alderson et al. 2007). 
2.5.4 Vasopressors 
Target of treatment
By definition, every patient in septic shock 
needs a vasopressor treatment for adequate 
perfusion pressure. Minimal data exist on an 
optimal blood pressure target to guide the va-
sopressor treatment. A MAP 60 mmHg to 65 
mmHg has been traditionally chosen because 
of the physiological autoregulation range. Au-
toregulation is a manifestation of local blood 
flow regulation. It is defined as the intrinsic 
ability of an organ to maintain a constant blood 
flow despite changes in perfusion pressure. 
Autoregulation operates especially well in vital 
organs like in the renal, cerebral, and coronary 
circulation. A MAP of about 60 mmHg to 65 
mmHg is considered as a threshold and below 
that the autoregulation of blood flow to vital 
organs ceases, resulting in pressure dependent 
regional blood flow, exposing organs to tissue 
hypoxia and organ dysfunction. 
Animal data show that the elevation of the 
normotensive MAP with norepinephrine does 
not increase regional perfusion in porcine 
sepsis if the MAP is within its autoregulatory 
range (Krouzecky et al. 2006). Two small hu-
man studies have also suggested that the el-
evation of MAP from 65 mmHg to 85 mmHg, 
with norepinephrine, neither affects meta-
bolic variables nor improves renal function 
or regional perfusion (Bourgoin et al. 2005; 
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LeDoux et al. 2000). It is unclear, however, if 
moderate hypotension even below 65 mmHg 
would be better than the aggressive use of va-
sopressor agents. No difference on survival was 
demonstrated when vasopressor agents versus 
placebo were administered to sustain arterial 
pressure in the course of experimental perito-
nitis in the murine model of septic shock (Tang 
et al. 1996). Also treatment with a selective 
NO-inhibitor incresed mortality despite the 
elevation of blood pressure (Bakker et al. 2004; 
Lopez et al. 2004). 
A recent consensus conference recom-
mended a target MAP over 65 mmHg for sep-
tic shock patients (Antonelli et al. 2007).
Vasopressor agents
Catecholamines, like dopamine, norepineph-
rine, epinephrine, and sometimes phenyleph-
rine are used as a vasopressor agent in septic 
shock. In recent years vasopressin, an endog-
enous hormone, and terlipressin, a synthetic 
analogue of vasopressin, have also been eagerly 
studied. Current guidelines suggest the use of 
dopamine or norepinephrine as a first line 
agent (Dellinger et al. 2004).
According to the recent Cochran system-
atic review, the current data do not support 
the use of any particular vasopressors in terms 
of reducing overall mortality in septic shock 
(Mullner et al. 2007). In observational cross-
sectional European cohort study (SOAP), the 
use of dopamine and epinephrine were as-
sociated with an increased mortality in sepsis 
(Vincent et al. 2006). Martin et al. reported a 
better survival with norepinephrine over other 
vasopressors (dopamine, epinephrine) in their 
prospective observational study with a logistic 
regression analysis (Martin et al. 2000) and nor-
epinephrine was more effective than dopamine 
in correcting sepsis induced hypotension in a 
non-randomized study (Martin et al. 1993). 
When dopamine alone is sufficient to restore 
the blood pressure, however, the outcome is 
generally favourable (Levy et al. 2005).
Vasopressin has been effective in increas-
ing the blood pressure of patients refractory to 
conventional vasopressor treatment. Vasopres-
sin in addition to norepinephrine leads to a sig-
nificant reduction in vasopressor requirement 
(Patel et al. 2002; Micek et al. 2007) although 
it alone may not be sufficient to restore blood 
pressure (Micek et al. 2007). The potential ad-
verse effects to regional circulation and cardiac 
function have reduced its clinical use. In an 
experimental study, high doses of vasopressin 
lead to a decrease in mesenteric and renal blood 
flows (Malay et al. 2004). It seems that the safe 
dose range for exogenous vasopressin in septic 
shock is narrow. The overall effect of low-dose 
vasopressin and norepinephrine to blood flow 
of the intestine or kidneys in septic shock has 
been mostly favorable, however, along with the 
increasing perfusion pressure (De Backer et al. 
2003; Farand et al. 2006).
The effect of vasopressin on mortality in 
septic shock was studied in a large prospec-
tive controlled trial (VASST, Vasopressin and 
Septic Shock Trial). The preliminary results 
(published in 28th International Congress of 
Critical Care and Emergency Medicine, Brys-
sel, 2007) showed that contrary to the hypoth-
esis, low-dose vasopressin reduced mortality 
compared to norepinephrine in a subgroup 
of patients with less severe sepsis (lower need 
for vasopressors) but had no advantage for 
patients with a high norepinephrine dose. In 
that study, low-dose vasopressin had no more 
significant side effects than norepinephrine. 
In a retrospective study by Luckner et al. the 
dose of NE before start of vasopressin was an 
independent predictor of mortality. The mor-
tality rapidly increased if NE dosages exceeded 
0.6 μg/kg/min before AVP infusion had been 
implemented (Luckner et al. 2005)
In few small trials terlipressin, a synthetic 
analogue of vasopressin, with a longer half 
life and a stronger affinity to vasopressin-1 
receptors, have been studied in catecholamine 
refractory septic shock. Its effect on blood 
pressure has been favorable, but possible side 
effects to cardiac function have been alarming 
(Albanese et al. 2005).
2.5.5 Inotropic medication
Target of treatment
In the 1980’s and 1990’s there was much enthu-
siasm to increase CO and DO2 to supranormal 
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values, thus mimicking the hemodynamic pro-
file of survivors of sepsis (Edwards et al 1989; 
Shoemaker et al. 1993). The studies aimed at 
some supranormal cardiac output, however, 
have failed to show benefit in mixed critically 
ill patients (Hayes et al. 1994; Gattinoni et al. 
1995). Later it was observed that increase in 
DO2 does not lead to an increase in VO2 in 
nonsurvivors (Hayes et al 1997), which may 
be a sign of cytopathic disturbances, mito-
chondrial dysfynction and microcirculatory 
failure in septic shock. The ability of patients to 
increase VO2 to a dobutamine infusion is asso-
ciated with a good outcome. This implies that 
patients whose cells are functioning in a nor-
mal manner do well and patients whose cells 
are no longer able to function normally have a 
poor outcome (Rhodes et al. 1999).
Cardiac function is often impaired in sep-
tic shock when assessed with echocardiogra-
phy or with radionuclide techniques. Current 
guidelines suggest the use of dobutamine as an 
inotropic medication in patients with a mea-
sured low cardiac output despite fluid resus-
citation (Dellinger et al. 2004). According the 
EGDT protocol, inotropic medication should 
be introduced according to the signs of insuf-
ficient perfusion, measured with ScvO2 (Rivers 
et al. 2001). Some have proposed that inotro-
pic medication should be started if the left 
ventricular ejection fraction is less than 40  % 
measured with echocardiography (Figure 4).
Inotropic agents
Dobutamine is generally considered as a treat-
ment of choice for sepsis-related myocardial 
depression (Dellinger et al. 2004). Dobutamine 
increases the cardiac index and stroke volume, 
although the heart rate also increase in most 
patients. Dobutamine increases regional blood 
flow in sepsis and has shown beneficial effects 
when used as a combination with vasopressor 
agents. No study has shown improved outcome 
with the use of dobutamine, however, and evi-
dence exists that high doses may have an ad-
verse effects to outcome (Hayes et al. 1994). 
Morelli et al. investigated the effects of levosim-
endan on systemic and regional hemodynam-
ics in dobutamine resistant septic myocardial 
depression. They found that levosimendan im-
proves systemic hemodynamics and regional 
perfusion in sepsis and is a safe and efficacious 
alternative to dobutamine (Morelli and Teboul 
2006). Levosimendan may improve right ven-
tricular performance and global perfusion in 
ARDS associated with septic shock (Morelli et 
al. 2006).
2.5.6 Adjuvant therapies
Corticosteroids
Cortisol is essential in regulating the impaired 
vasomotor tone of the vasculature. Cortisol 
decreases the NO mediated vasodilatation, 
sensitizes the receptors to catecholamines, 
and affects the distribution of body fluids by 
improving the endothelial barrier function 
(Marik and Zaloga 2002; Prigent et al. 2004; 
Rhen and Cidlowski 2005). The use of low 
dose corticosteroids improves the shock reso-
lution in septic shock, although the effect on 
mortality has been controversial (Annane et al. 
2004; Keh and Sprung 2004). In a recent Cor-
ticus trial low dose corticosteroids resulted in 
earlier resolution of shock, but the recurrence 
of shock or new infections occurred more of-
ten in the treatment group and corticosteroids 
showed no benefit in mortality (unpublished). 
The improvement of hemodynamics is not pre-
dicted by the results of an adrenocorticotropin 
(ACTH) stimulation test (Morel et al. 2006).
Activated protein C
Recombinant human activated protein C 
(rhAPC) improved the outcome of adult pa-
tients with severe sepsis and septic shock (Ber-
nard et al. 2001). The positive effect was most 
pronounced in those with more severe sepsis. 
In one retrospective study rhAPC decreased 
the norepinephrine dose required to maintain 
arterial pressure (Monnet et al. 2005). The 
possible beneficial effects of rhAPC on hemo-
dynamics are likely multifactorial. In experi-
mental models rhAPC decrease nitric oxide 
synthase (NOS) activity and TNF-α produc-
tion, but no significant effect on cytokines has 
been detected in human studies (Sennoun et al. 
2007). Some in vivo and in vitro studies have 
shown that RhAPC may improve endothelial 
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barrier function and thus decrease the vascular 
permeability in sepsis (Looney and Matthay 
2006).
Others
The nitric oxide synthase inhibitor, NG-meth-
yl-L-arginine hydrochloride, promoted the 
resolution of shock in a multicentered, ran-
domised, placebo-controlled study (Bakker et 
al. 2004). The phase III trial was prematurely 
terminated, however, because of increased 
mortality (Lopez et al. 2004). Methylene blue, 
an inhibitor of nitric oxide, increases the mean 
arterial pressure and systemic vascular resis-
tance in septic shock and vasopressor require-
ments decrease. Studies on the influence on 
outcome are lacking (Kirov et al. 2001; Kwok 
and Howes 2006). The inhibition of KATP chan-
nels with sulfonylureas has restored MAP in 
experimental endotoxemic shock (Lange et al. 
2006). One study investigated the inhibition 
of KATP channels with glibenclamide in human 
septic shock, but failed to achieve a reduction 
in norepinephrine (Warrillow et al. 2006). 
Outside the vasculature, KATP channels may 
also represent a protective mechanism against 
cellular damage. (Buckley et al. 2006).
Different modalities of high-volume or iso-
volume hemofiltration have improved hemo-
dynamics in septic shock patients with mul-
tiple organ dysfunction (Joannes-Boyau et al. 
2004; Ratanarat et al. 2005; Haase et al. 2007), 
but the indications in septic shock without re-
nal failure are not clear (Cole et al. 2002).
2.6 OUTCOmE OF SEPTIC SHOCK
The mortality rate is sepsis increases with the 
severity of the sepsis. Rangel-Frausto et al. 
prospectively evaluated the mortality rate in 
relation to the sepsis criteria of 3708 patients. 
Mortality increased with the number of criteria 
for systemic inflammatory response syndrome 
(SIRS) or if the clinical sepsis severity increased. 
The mortality rate without SIRS criteria was 
3  %, while it was 7  % with two, 10  % with three, 
and 17  % with four SIRS criteria. Mortality rate 
was 20  % in severe sepsis and 46  % in septic 
shock (Rangel-Frausto et al. 1995). Alberti et 
al found no difference in hospital mortality 
rate between patients with infection and with 
sepsis (i.e. infection and SIRS criteria) without 
organ dysfunction, while presence of organ 
dysfunction or shock had a strong prognostic 
significance (Alberti et al. 2003). 
The hospital mortality rate of septic shock in 
epidemiological studies has varied from 29  % 
to 82  % (table 2) and in placebo arms of ran-
domized trials, hospital mortality has varied 
from 30  % to 87  % (Dellinger 2003). The wide 
variations in observed mortality depend partly 
on the different selection of patients in studies. 
Differences in ICU admission policy and dif-
ferences in critical care organisations in differ-
ent countries may also have influenced results 
when only patients inside ICU are evaluated. 
Shortage of ICU beds leads to tight admission 
criteria with only the most critical patients be-
ing admitted, hence the mortality rate is prob-
ably higher.
The outcome of septic shock has improved 
over time. When 131 studies from 1958 to 
1997 with over 10 500 patients were evalu-
ated, evidence existed of a small improvement 
in the survival rate from septic shock over the 
last few decades (Friedman et al.1998). Impor-
tant studies that have reported a signifigant 
mortality benefit and that have changed the 
treatment in sepsis have been published in the 
21st century. Rivers et al. demonstrated a 16  % 
decrease in absolute 28-day mortality with 
EGDT (Rivers et al. 2001). RhAPC reduced 
absolute mortality by 6  % in severe sepsis Ber-
nard et al. 2001) and low-dose steroid replace-
ment decreased mortality by 10  % for those 
septic shock patients, who did not respond to 
adrenocorticotropin test (Annane et al. 2002). 
In addition, the control of glucose balance 
with insulin infusion showed a 3.7  % mortal-
ity reduction in critically ill ICU patients and 
lung-protective ventilatory treatment has re-
duced mortality in acute respiratory distress 
syndrome, which occurs commonly in septic 
shock. Based on these results, the European 
Society of Intensive Care Medicine (ESICM), 
International Sepsis Forum (ISF), and Society 
of Critical Care Medicine (SCCM) started the 
world-wide Surviving Sepsis Campaign (SSC) 
with the target of achieving a 25  % reduction in 
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sepsis mortality by 2009. The SSC aims to reach 
this target with a multipoint strategy; build-
ing awareness of sepsis, improving diagnosis, 
increasing the use of appropriate treatments, 
educating healthcare professionals, improving 
post-ICU care, developing guidelines and fa-
cilitating data collection for audit and feedback 
(www.survivingsepsis.com).
Long-term outcome data after treatment of 
septic shock is sparse. In the Finnsepsis Study 
one-year mortality after ICU-treated severe 
sepsis or septic shock was 40.9  % (Karlsson et 
al. 2007). Jagodic et al. found that the two-year 
mortality of severe sepsis or septic shock after 
treatment in surgical ICU was 67  %, which was 
higher than after trauma (43  %)(Jagodic et al. 
2006). In the PROWESS trial, one-year surviv-
al of patients with severe sepsis or septic shock 
was 53  % for the treatment group and 49  % for 
the placebo group (Angus et al. 2004). In a pro-
spective study of patients with sepsis syndrome 
in the ED, the overall one-year mortality was 
22  %. The presence of SIRS criteria alone had 
no prognostic value, but each additional organ 
dysfunction increased the adjusted one-year 
mortality hazard by 82  % (Shapiro et al. 2006). 
The one-year mortality after bloodstream in-
fection associated sepsis without shock was 
36  % and with shock 61  %. Surgical diagnosis 
and increasing age were independently associ-
ated with late mortality (Laupland et al. 2005). 
Weycker et al. obtained data from the U.S. 
health insurance database for the study on the 
long-term outcome of over 16 000 patients that 
were hospitalized because of severe sepsis in 
1991–2000. He found an one-year mortality of 
51.4  % and five-year mortality of 74.2  %. Ad-
vanced age, comorbidities, organ dysfunction, 
and hospital discharge to another facility were 
associated with a higher mortality (Weycker et 
al. 2003). Quartin et al. reported that among 
30-day sepsis survivors, sepsis reduced the re-
maining mean life span from a predicted 8.0yrs 
to 4.1yrs (Quartin et al.1997)
The 28-day, or hospital mortality, is gener-
ally used as an end-point in clinical trials. The 
mortality of septic shock, however, increased 
constantly even after first month or first hos-
pitalization period. Exact reasons for this late 
mortality are not clear, although the risk is 
increasing with advanced age, co-morbidities, 
and disease severity at the beginning. Longer 
follow-up and studies on the reasons for late 
deaths are warranted in future trials (Vincent 
2004). 
Sepsis survivors may suffer from residual 
organ dysfunction. Patients may have lose 
their extremities or have severe impairments 
of muscle function. Persistent symptoms such 
as dyspnea, fatigue, depression, and impaired 
functional status may lead to reduced quality 
of life. The long-term health-related quality of 
life (HR-QoL) of survivors of sepsis is lower 
than that of the general population (Heyland 
et al. 2000), but it might not differ from other 
patients who had survived critical illness not 
involving sepsis (Granja 2004; Jagodic et al. 
2006).
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3 AIMS OF THE STUDY
The objective of this study was to evaluate different aspects of hemody-
namic patterns in septic shock, especially components of early treatment 
and monitoring. The specific aims were:
1. To assess the impact of hemodynamic variables on the outcome of 
patients with septic shock and to identify the optimal threshold values 
related to outcome with special reference to continuously monitored 
mean arterial pressure (MAP) and mixed venous oxygen saturation 
(SvO2). (I)
2. To assess the correlation and agreement of central venous oxygen 
saturation (ScvO2) and mixed venous oxygen saturation (SvO2) and 
to compare ScvO2–SvO2 difference to lactate, oxygen-derived, and 
hemodynamic parameters in early septic shock. (II)
3. To evaluate the predictive value of NT-proBNP on mortality in a large 
unselected patient population with severe sepsis and septic shock. (III)
4. To determine, how the early treatment guidelines were adopted and 
what was the impact of early treatment on mortality in septic shock 
patients in Finland. (IV)
Figure 6. The flowchart of inclusion in studies I–IV
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4 PATIENTS AND METHODS
4.1 PATIENTS
Altogether 410 patients were included in stud-
ies I-IV. The flowchart of inclusion is presented 
in Figure 5. The demographics of the study pa-
tients are presented in Table 3.
Study I was a retrospective cohort study 
which was conducted in one nine-bed medi-
cal-surgical intensive care unit (ICU) at the 
Helsinki University Hospital. All 1419 con-
secutive patients that were admitted to the ICU 
between January 1, 1999 and January 30, 2002 
were considered eligible. The 111 patients with 
a discharge diagnosis compatible with sepsis 
(sepsis, pneumonia, meningitis, or peritonitis) 
and a need for vasopressor support during the 
first 48 h constituted the final study population 
with septic shock.
Study II was a prospective study conducted 
in two Finnish ICUs from November 2004 to 
June 2005. Sixteen patients with septic shock 
fulfilling the criteria set by the APCCP/SCCM 
Consensus Conference were included. In addi-
tion a norepinephrine dose over 0.1 μg/kg/min 
for maintaining mean arterial blood pressure 
over 65 mmHg was required for inclusion in 
addition. 
Studies III and IV were substudies of a pro-
spective observational cohort study on the in-
cidence and prognosis of sepsis in Finland (the 
Finnsepsis study). The Finnsepsis study was 
conducted over a four-month period (from 
November 1, 2004 to February 28, 2005) in 
24 ICUs in Finland. All adult patients (≥ 18 
years) that were admitted in the participating 
ICUs during the study period were screened 
daily for the criteria of severe sepsis and septic 
shock proposed by ACCP/SCCM. All patients 
filling these criteria; known or suspected infec-
tion, with two or more criteria of the systemic 
inflammatory response syndrome, and at least 
one sepsis-induced, new organ failure were in-
cluded to the Finnsepsis study. A patient was 
included to study III, if the consent for blood 
tests was obtained from the patient or their le-
gal representatives. Study IV included patients 
who had community-acquired sepsis, were 
admitted directly from the ED to ICU, and ful-
filled the criteria of septic shock according to 
the attending physicians. A total of 55 patients 
were included in both studies III and IV.
Comparison of demographics and charac-
teristics of patients are shown in Table 3.
4.2 STUDy DESIGNS
Summary of the study designs is shown in 
Table 4.
Study I
In the study I we analyzed the common he-
modynamic variables as outcome indicators 
in septic shock during the first six and 48 
hours separately. In addition we evaluated, 
whether the time or area under critical MAP 
or the SvO2 level would be a better predictor 
of survival than the mean values of these or 
the other hemodynamic variables and which 
threshold level is the best discriminative level 
between survivors and non-survivors. An ex-
ample of this method is shown in Figure 6. 
Both MAP and SvO2 were recorded from the 
database every 10 mins (each value was con-
sidered representative of the values within the 
previous 10 mins). Ppao, CVP, CI, and SV were 
recorded every one to six hours. Serum lactate 
was recorded upon arrival and on day two. If 
the patient expired within the 48-h monitor-
ing period, the last hours data were excluded. 
A 30-day mortality rate was assessed.
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Table 3.Demographics of the patients in Studies I - IV
Study I Study II Study III Study IV
Number of patients 111 16 254 92
Age 52 (39-63) 51 (44-62) 60 (49-72) 57 (49-62)
Male sex 62 (56%) 13 ( 81% ) 175 (69%) 67 (73%)
Apache II 17 (11-22)** 23 (18-29) 23.5 (18-29) 26 (20-33)
SOFA  on 1.day 8 (6-12) 10 (9-12) 8 (6-11) 10 (7.25-12)
ICU mortality 33 (30%) NA 34 (13%) 20 (22%)
Hospital mortality* 36 (33%)* 6 ( 38% ) 67 (26%) 30 (36%)
 Norepinephrine medication on day 1 93 (84%) 16 (100%) 178 (70%) 79 (86%)
Maximal dose of norepinephrine (ug/kg/min) 0.15 (0.05-0.46) 0.26 (0.16-0.36) 0.18 (0.08-0.34) 0.35 (0.10-0.43)
Ventilator treatment 104 (94%) 16 (100%) 153 (60%) 68 (74%)
Positive blood culture 61 (55%) 5 (31%) 72 (28%) 42 (46%)
Primary site of infection
    Lung 47 (42%) 6 (38%) 106 (42%) 45 (49%)
    Intra-abdominal 15 (14%) 6 (38%) 81 (32%) 15 (16%)
    Central nervous system 8 (7%) 1 (6%) 6 (2%) 2 (2%)
*30-day mortality in Study I
** Data available from 66 patients
Data are expressed as number (percentage) or median (25-75 percentiles)
 
Study II
In this study we evaluated the correlation and 
the agreement of ScvO2 and SvO2 and also 
compared the ScvO2–SvO2 difference to lactate, 
oxygen derived and hemodynamic parameters 
during early severe septic shock in ICU. Si-
multaneous blood samples were drawn slowly 
from the distal port of the unwedged PAC for 
SvO2 and from the side port of the introducer 
for ScvO2 immediately after the patient inclu-
sion and every six hours thereafter up to 24 h. 
Arterial samples were drawn from the arterial 
catheter. Hemodynamic measurements and 
measurements of arterial plasma lactate level 
were performed immediately after blood sam-
pling. 
Figure 7. An example of recording the mean arterial pressure during the first 48h in the ICU in Study I.. Arrows 
are the threshold values used in calculations. The hypotension area/time is calculated as the total area/time of 
MAP values lower than the threshold, divided by the duration of the monitoring time. Hypotension area under 
60 mmHg is shown in grey. Black line indicates the hypotension time under 60 mmHg
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Study III
In this study we evaluated the predictive value 
of NT-proBNP regarding hospital mortality 
in severe sepsis and septic shock in a large, 
unselected, representative patient population. 
We also assessed the clinical characteristics 
of patients with elevated NT-proBNP. Blood 
samples for NT-proBNP analyses were ob-
tained from an indwelling arterial catheter or 
by venapuncture at inclusion and 72 hours 
thereafter. Both ICU and hospital mortality 
was recorded. One-year mortality data was ob-
tained from Statistics Finland.
Study IV
In this prospective substudy of the epidemio-
logical cohort study, we evaluated the success 
of the early sepsis treatment in 24 Finnish 
ICUs.
Patients were divided into two groups ac-
cording to the number of achieved targets.
The group ≥ 4 consisted of patients who 
reached four or more treatment targets and the 
group ≤ 3 of those with three or less targets. 
Also the impact of separate treatment targets 
concerning the outcome was evaluated.
The ICU and hospital mortality was record-
ed from hospital records and one-year mortal-
ity data from Statistics Finland.
4.3 LABORATORy mEASUREmENTS
Plasma N-terminal pro-brain natriuretic 
peptide (III)
Blood samples were obtained from an indwell-
ing arterial catheter or by venapuncture into 
Li-heparin containing tubes. The plasma frac-
tion was separated and samples were stored 
at –20 °C or colder at the enrolling site before 
being sent to the Helsinki University Hospital, 
where samples were stored at –80 °C. Samples 
were analysed 9–13 months later in batches af-
ter a single thaw. The plasma concentration of 
NT proBNP was determined using a commer-
cially available immunoassay (Elecsys proBNP, 
Roche Diagnostics, Mannheim, Germany) on 
an Elecsys 2010 automatic analyzer (Roche 
Diagnostics). All laboratory analysis was per-
formed in a single acredited laboratory (Hel-
sinki University Central Hospital Laboratory, 
HUSLAB).
Plasma lactate (I–IV))
Plasma lactate levels were measured from an 
indwelling arterial catheter by a photometric 
method. Although the measurement of lactate 
was not included in the study protocol in stud-
ies III and IV, it was measured as a routine clin-
ical measurement and the evaluation of lactate 
values was prospectively defined.
Other
Although no specified laboratory sample pro-
tocol was chosen, routine tests were taken daily 
as a part of patient follow-up and for organ 
failure and disease severity scores. These tests 
included blood gas analyses, serum creatinine, 
urea and bilirubin concentrations, hemoglobin 
and hematocrit, white blood cell count and 
platelets. In study III the estimated creatinine 
clearance was calculated using the Cockcroft 
and Gault formula:
(140 – Age) × weight (kg) × F} / (Plasma Crea-
tinine × 48.816). Where F = 1 if male, and 0.85 
if female (Cockcroft and Gault 1976).
4.4 HEmODyNAmIC mONITORING 
AND mEASUREmENTS
Pulmonary artery catheter (PAC) or  
central venous catheter (I–IV)
Only study II included PAC insertion in the 
study protocol, but PAC derived data was used 
in studies I and III when available. In these 
studies pulmonary artery catheterization or 
central venous catheterization was performed if 
the local intensivist deemed it necessary. Com-
monly the use of a pulmonary arterial catheter 
was considered appropriate if norepinephrine 
was used. In study I, 100 of the 111 (90  %) pa-
tients had PAC, in study II all 16 patients and in 
study III 121 (48  %) patients had a pulmonary 
artery catheter and an additional 95 patients 
(38  %) had central venous catheter inserted. In 
study II a four-lumen pulmonary artery cathe-
ter (PAC) with introducer (7.5 F Paceport Oxi-
metry TD Catheter with AMC Thromboshield 
780HF75, Edwards Lifesciences LCC, Irvine, 
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CA, USA) was inserted. A typical wedge pres-
sure tracing with the balloon inflated and chest 
X-ray confirmed the correct placement of the 
catheter in the West zone 3 position. 
The cardiac output (CO) was determined 
with the thermodilution method via PAC by 
injecting 10 mL of isotonic saline through the 
proximal port of PAC. The CI was computed by 
dividing CO by the patient’s body surface area. 
Three to five measurements were obtained and 
averaged.
SvO2 (I, II, IV) and ScvO2 (II, IV)
In study I, SvO2 was continuously measured 
with a fiberoptic catheter by reflectance oxim-
etry. 
In study II, the SvO2 samples were drawn 
slowly from the distal port of the unwedged 
PAC and ScvO2 samples from the side port of 
the introducer. Oxygen saturation was deter-
mined photospectrometrically with a co-oxi-
metry (Ciba-Corning 850 and 855, Medfield, 
MA, USA).
In study IV, SvO2 (or ScvO2) was measured 
either with the fiberoptic method or with co-
oximetry using separate samples.
4.5 INTERVENTIONS 
Besides laboratory analyses (I, II, III) and oxi-
metric and hemodynamic measurements (II), 
patients were treated according to the discre-
tion of attending physicians without special 
treatment protocols and without therapeutic 
interventions.
4.6 DATA COLLECTION
During the inclusion period of study I, our unit 
used an ICU clinical data management system 
(CareVue, Hewlett-Packard, Boston, MA, USA) 
which automatically stored all physiologic data 
displayed in the database of the monitors (Da-
texAS3, Datex-Ohmed, Helsinki, Finland) at a 
five-minute sampling frequency as well as all 
laboratory and medication data. The requisite 
data was extracted retrospectively from the 
database. 
Studies III and IV included patients from 24 
ICUs from 21 hospitals. All data were collected 
daily by local study nurses or investigators (Ap-
pendix). Data was stored through an internet-
based Finnish intensive care quality consortion 
(Intensium Ltd.Kuopio, Finland).
4.7 OUTCOmE mEASURES
Mortality
The 30-day mortality (Study I), hospital mor-
tality (Study III and IV), and one-year mortal-
ity (Study III and IV) data were acquired from 
the hospital records and Central Population 
Registry of Finland.
The standardized mortality ratio (SMR)
The standardized mortality ratio (SMR) was 
calculated as the ratio of observed hospital 
mortality over the predicted hospital mortality 
(Study IV). Probability of hospital death was 
calculated using the Simplified Acute Physiol-
ogy Score (SAPS) II.
Disease severity scores 
SOFA (Sequential Organ Failure Assess-
ment (Vincent et al 1998)
SOFA score evaluate status of the following or-
gan systems separately: Respiration, coagula-
tion, hepatic, cardiovascular, renal, and central 
nervous system. The SOFA score were calcu-
lated for days one and two (Study I), for day 
one (study II and IV) or for day one and three 
(Study III).
Acute Physiology and Chronic Health 
Evaluation (APACHE) II score (Knaus et 
al 1985) and Simplified Acute Physiology 
Score (SAPS) II (Le Gall, Lemeshow and Saul-
nier 1993)
To evaluate the severity of illness APACHE II 
and SAPS II scores were calculated for the first 
24 hours in the ICU (Study I–IV)
4.8 STATISTICAL ANALySES
Statistical significance: The level of 
p<0.05 was considered statistically significant 
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in all tests. The analyses were performed us-
ing the SPSS 10.1.3 (I) or 13.0 (II–IV) software 
(SPSS,Chicago,Ill.).
The Kolmogorow-Smirnov test was used for 
testing the normality of continuous variables 
(II, III).
Mann-Whitney U test was used for the 
comparison of continuous variables of two 
samples of observations like demographic, 
hemodynamic or laboratory data between sur-
vivors and non-survivors (I–III) or patients in 
different groups (IV).
Chi-Square or Fisher’s exact tests were 
used for testing the difference between two 
samples of categorical variables. Fisher’s exact 
was used if the number of cases in a sample was 
below five (I–IV).
Spearman’s rank correlation test was 
used for determining the relationship between 
two continuous variables, which were not nor-
mally distributed like comparison of NT-proB-
NP and physiological and laboratory variables 
or SvO2–ScvO2 difference and hemodynamic 
or perfusion variables (I–III).
Linear regression analysis was used to find 
the potential confounding factors that would 
best predict the value of the dependent variable 
(NT-proBNP). The variables that first yielded 
significance in the univariate model, were 
tested with a linear regression analysis using 
log-transformed NT-proBNP, because values 
of NT-proBNP were not normally distributed 
(III).
Bland-Altman analysis is a statistical 
method, which assess the agreement between 
two methods of clinical measurement. It can 
be used for comparison of a new method with 
an established one to see whether they agree 
sufficiently for the new one to replace the old. 
The Bland-Altman graph plots the difference 
between two measurements against their aver-
ages. The Bland-Altman analysis was used to 
evaluate the agreement between ScvO2 and 
SvO2 in study II.
Intraclass correlation (ICC) was used to 
measure the statistical significance of correla-
tion between ScvO2 and SvO2 measurements of 
patients at different time-points (II). The ICC 
was used instead of the Pearson correlation, 
because of repeated measurements of a single 
patient at five separate time-points, which 
made the data intracorrelated and not totally 
independent.
Friedman test is a nonparametric test for sev-
eral related samples. It was used to detect the 
differences between ScvO2 and SvO2 measure-
ments across different time-points and also 
across different levels of ScvO2 (II).
Kruskal-Wallis test is a non-parametric 
method for comparing the medians between 
two or more samples to determine if these have 
come from different populations. The Kruskal-
Wallis test was used in study III where the study 
population was divided to groups according to 
quartiles of APACHE II, SAPS II, and SOFA 
scores and the differences of NT-proBNP be-
tween groups was assessed (III).
Kaplan-Meier test was used to evaluate one-
year mortality differences in studies III and IV.
Multivariate forward logistic regres-
sion analysis was used to test the indepen-
dent effect of the variable on the outcome (I, 
III, IV).
Receiver operating characteristic 
curve (ROC) analysis was used in study III 
for finding the best predictive cut-off values of 
NT-proBNP for predicting mortality. The best 
cut-off values are defined as the threshold val-
ues that maximized the sum of the sensitivity 
and specificity.
Areas under the ROC curve (AUC) were 
used for determining the predictive accuracy 
of variables. AUCs were calculated for mortal-
ity prediction using all MAP and SvO2 derived 
parameters as predictive variables in study I, 
and NT-proBNP in both time points as predic-
tive variables in study III.
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Diagnostic accuracy, sensitivity, speci-
ficity, positive and negative predictive 
values of NT-proBNP for mortality predic-
tion was assessed as follows:
*NT-proBNP values above cut-off
**NT-proBNP values below cut-off
Sensitivity = true positives/(true positives+false negatives) = A/(A+B)
Specificity = true negatives/(true negatives+false positives) = C/(C+D) 
Positive predictive value = true positives/(true positives+false positives) = A/(A+C) 
Negative predictive value = true negatives/(true negatives+false negatives)= B/(B+D)
Accuracy = (true positives + true negatives)/all = (A+D)/(A+B+C+D)
Condition
Dead Alive
Test
outcome
Positive* A=true Positive C=fase Positive A+C
Negative** B=false Negative D=true Negative B+D
A+B C+D
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6 RESULTS
late to CI (p = 0.036) and to DO2 (p = 0.007), 
but detected no correlation to other measured 
variables or to the dose of norepinephrine. We 
concluded that for clinical use the agreement 
of ScvO2 and SvO2 is not adequate and that 
SvO2 is not estimated on the basis of ScvO2 in 
septic shock.
6.3 NT-PROBNP AS A PROGNOSTIC 
FACTOR IN SEVERE SEPSIS AND 
SEPTIC SHOCK (III)
The NT-proBNP values upon admission var-
ied from 55 pg/mL to 146  592 pg/mL (median 
4396 pg/mL), and at 72 hours from 39 pg/mL 
to 247  812 pg/mL (median 2889 pg/mL). The 
NT-proBNP levels upon admission were sig-
nificantly lower in hospital survivors (median 
3479 pg/mL; 25th and 75th percentiles 1102 pg/
mL and 9970 pg/mL) than non-survivors 
(median 7908 pg/mL; 25th and 75th percentiles 
2658 pg/mL and 20855 pg/mL; p  = 0.002). 
This difference persisted at 72 hours (median 
2354 pg/mL; 25th and 75th percentiles 631 pg/
mL and 6362 pg/mL vs. 5688 pg/mL; 25th and 
75th percentiles 1479 pg/mL and 17972 pg/
mL; p =  0.002) (Figure 8). In ROC analysis the 
area under the curve (AUC) of NT.proBNP for 
hospital mortality upon admission was 0.631 
(95  % Cl 0.549–0.712, p = 0.002) and at 72-
hour 0.648 (95  % Cl 0.554–0.741, p = 0.002).
The best cut-off value of NT-proBNP upon 
admission for hospital mortality was 7090 pg/
mL with a sensitivity of 58  % (95  % Cl 45–
69  %), a specificity of 66  % (95  % Cl 59–73  %), 
a positive predictive value of 38  % (95  % Cl 
29–48  %), a negative predictive value of 81  % 
(95  % Cl 74–87  %), and an accuracy of 64  %. 
The best cut-off value of NT-proBNP after 72 
hours was 8948 pg/mL with a sensitivity of 
45  % (95  % Cl 30–60  %), a specificity of 81  % 
(95  % Cl 74–86  %), a positive predictive value 
6.1 PREDICTION OF mORTALITy 
ACCORDING TO HEmODyNAmIC 
VARIABLES (I)
The study showed that in septic shock dur-
ing first six hours in ICU the most important 
variables concerning mortality were the mean 
MAP (p=0.001) and lactate upon arrival 
(p=0.02). When a patient was followed for up 
48 hours the mean MAP, the mean CVP, and 
a hypoperfusion area (SvO2) under 70  % were 
independently associated with mortality by a 
logistic regression analysis. Receiver operation 
curves regarding the 30-day mortality were 
plotted for allthe MAP and SvO2 derived vari-
ables. The highest AUC values were found for 
the hypotension area under 65 mmHg (AUC 
0.853, 95  % CI 0.772–0.934) and for the hy-
poperfusion time under 70  % (AUC 0.747, 
95  % CI 0.618–0.876). According to these the 
best discriminative threshold value concerning 
mortality is 65 mmHg for MAP and 70  % for 
SvO2.
6.2 SVO2 VERSUS SCVO2  
IN SEPTIC SHOCK (II)
In early severe septic shock, simultaneous val-
ues of ScvO2 and SvO2 correlated significantly 
(intraclass correlation coefficient 0.89, 95  %CI 
0.82–0.93, p<0.001). The mean SvO2 was be-
low the mean ScvO2 at all time points during 
the first 24 hours. When simultaneous mea-
surements were evaluated with the method 
proposed by Bland and Altman, the agreement 
of ScvO2 and SvO2 was not adequate.
The agreement between ScvO2 and SvO2 by 
the Bland–Altman plot showed that the bias 
of difference was 4.2  % (95  % limits of agree-
ment from –8.1  % to 16.5  %). We found that 
the difference between simultaneous ScvO2 
and SvO2 (∆[ScvO2–SvO2]) inversely corre-
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of 40  % (95  % Cl 27–54  %), a negative predic-
tive value of 84  % (95  % Cl 77–89  %), and an 
accuracy of 73  %. The Kaplan-Maier curves for 
one-year mortality according the best cut-off 
limits are shown in Figure 9.
In the univariate logistic regression analysis 
the significant predictors (p < 0.05) for hospi-
tal mortality were age, SAPS score, APACHE 
II score, SOFA score, lowest MAP, maximal 
dose of norepinephrine and epinephrine, and 
plasma lactate. These and NT-proBNP values 
were entered into a multiple forward stepwise 
logistic regression model. Independent pre-
dictors of hospital mortality were the SAPS 
II score (p  < 0.001) and 72-hour NT-proBNP 
(p  = 0.014). 
The NT-proBNP upon admission sig-
nificantly correlated to the highest Paop 
(p < 0.001), eCrCl (p  = 0.002), lowest platelet 
count on the first day (p  = 0.03), and positive 
Figure 8. N-terminal pro– brain natriuretic peptide (NT-proBNP) levels of hospital survivors and nonsurvivors at 
admission and 72 hrs thereafter. Data are presented as median values (line) with 25th and 75th percentiles (boxes) 
and 5th and 95th percentiles (whiskers).
Figure 9. Kaplan-Meier survival curves according to N-terminal pro–brain natriuretic peptide (NT-proBNP) levels 
at admission (A) and at 72 hrs (B). Cut-off limits are best cut-off limits that predict hospital mortality. From 
Study III.
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blood culture (p =  0.04) according to a linear 
regression analysis. After 72 hours the linear 
regression analysis showed that only eCrCl 
(p  < 0.001) had an independent effect on the 
NT-proBNP value.
6.4 LACTATE AS A PROGNOSTIC 
FACTOR IN SEPTIC SHOCK (I, III, IV)
According to Study I, serum lactate upon ar-
rival to ICU was significantly associated with 
mortality (p  = 0.02) when only the first six 
hours hemodynamic variables were assessed 
with the logistic regression analyses. When the 
first 48 hours were evaluated, however, the ad-
mission lactate was not significant anymore. 
In Study III and IV, the first lactate value 
and the highest value during the first 24 hours 
in ICU were recorded. According to the ROC 
analysis, in Study III, which also included pa-
tients without septic shock, the AUC of the first 
lactate value was 0.665 (95  % CI 0.586–0.744) 
and 0.686 (95  % CI 0.606–0.766) for hospi-
tal mortality. In Study IV the corresponding 
AUCs were 0.794 (95  %CI 0.674–0.913) of the 
first lactate and 0.761 (95  % CI 0.626–0.897) of 
the first day maximal lactate (p < 0.001 for all)
6.5 EARLy TREATmENT OF SEPTIC 
SHOCK IN FINLAND (IV)
All predefined end-points of early treatment 
concept were completed for 6 of 92 patients 
(6.5  %). When single targets were analysed 
separately, blood cultures were obtained most 
often (79 of 92, 86  %). The ScvO2/SvO2 target 
was measured in time for 18 patients, but the 
goal was achieved for only 10 patients (11  %). 
The CVP was measured during the first six 
hours for 34 patients and the goal of over 8 
mmHg was achieved for 29 patients (32  %). 
Lactate was measured during the first 6 six 
hours in 53 (58  %), a MAP of over 65 mmHg 
was achieved in 68 (74  %) and antibiotics were 
started during the first three hours in 49 (53  %) 
patients. The serum lactate value was mea-
sured in the ED before ICU transfer for 20 of 
the 92 patients (22  %). CVP was measured in 
the ED for two patients and neither ScvO2 nor 
SvO2 was measured in the ED or the ICU for 35 
(38  %) patients. Antibiotics were started before 
ICU admission for 46 (50  %) patients.
In an univariate analysis of separate treat-
ment targets, the delay in the start of antimi-
crobic treatment within three hours from ED 
admission was significantly associated with 
hospital mortality (p  = 0.04). In a forward 
logistic regression analysis, the delay on the 
start of the antibiotics within three hours was 
an independent predictor of mortality when 
all separate targets were used as independent 
variables (p  = 0.04). When APC treatment, 
low-dose steroid treatment, APACHE II, and 
SOFA scores were added to the analysis, only 
the APACHE II score (p  < 0.001) was an inde-
pendent predictor of hospital mortality. 
When the one-year mortality was ana-
lyzed, the start of antibiotics within three 
hours (p  = 0.001) and the APACHE II value 
(p  = 0.001) were independent predictors of 
mortality in a logistic regression analysis. If 
antibiotic treatment was started within three 
hours, one-year mortality was 33  % (16 of 49 
[95  % CI 21–47  %]), while it was 72  % (31 of 
43 [95  % CI 57–83  %]) if the treatment was 
delayed. 
The Kaplan-Maier curve of mortality, ac-
cording to the start of the antibiotics within 
three hours, is shown in Figure 10. 
Figure 10. The Kaplan-Maier curve about mortality 
according the start of the antibiotics within three 
hours. From Study IV.
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The hospital mortality of those 33 patients 
who reached four to six treatment targets 
(group ≥ 4) was 24  % (8 of 33 [95  % CI 13–
41  %]) compared to 42  % (25 of 59 [95  % CI 
31–55  %]) of those 59 patients who reached 
three targets or less (group ≤ 3) (p = 0.08). The 
median delay from hospital admission to ICU 
transfer was 1.6 hours (0.7, 2.1) in group ≥ 4 
and 3.5 hours (2.0, 8.9) in group ≤ 3. The se-
verity of disease assessed with the APACHE II 
or SOFA score had no influence on the early 
treatment success.
6.6 mORTALITy (I, III–IV)
According to the combined results of Studies I 
and IV, the ICU mortality rate of septic shock 
was 26  % (53 of 203 patients): 33/111(30  %) in 
Study I and 20/92 (22  %) in Study IV. The hos-
pital mortality rate in Study IV in the overall 
population of septic shock patients was 36  % 
(33/92), and the 30-day mortality in Study I 
was 33  % (36/111). In Study III, which includ-
ed the patients with severe sepsis and septic 
shock, the ICU and hospital mortality rates of 
the study patients were 13  % (34 of 254) and 
26  % (67 of 254) (Table 3, page 36). 
The one-year mortality was assessed in 
Studies III and IV. It was 51  % (47/92) accord-
ing to Study IV in septic shock patients and 
40  % (102 of 254) according to Study III in 
severe sepsis and septic shock.
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7 DISCUSSION
Strengths and weaknesses of the study
The results of this study offer an aid for clini-
cians in their every-day work. We showed the 
importance of adequate MAP and SvO2 as well 
as the optimal thresholds concerning the out-
come with a huge amount of hemodynamic 
measurements. The predictive value of NT-
proBNP was shown prospectively with rep-
resentative and large patient population. We 
proved the disagreement of ScvO2 and SvO2 
measurements in septic shock during the ICU 
treatment, which might affect on monitoring 
methods in ICUs. Furthermore, we showed 
the reality of an early treatment of septic shock 
nationwide in Finland, which might help us to 
improve the treatment of septic patients. Al-
though the number of patient was quite small, 
this does not impair the generalization of the 
results to all patients with community aquired 
septic shock.
Some limitations of the studies can be ad-
dressed. First the optimal time point to assess 
the mortality after septic shock is not clear al-
though the hospital mortality is the most used 
time point. Many patients suffering sepsis are 
transferred from the hospital to rehabilitation 
centers or to nursing homes where they will 
probably die and never actually return home. 
Hospital mortality rate does not tell the true 
mortality concerning this issue. The 28-day or 
30-day mortality is not good either, because 
hospital length of stay after sepsis is very long. 
We used the 30-day mortality in Study I and 
hospital mortality in Study III and IV. In addi-
tion, one-year mortality was evaluated in Stud-
ies III and IV.
The retrospective nature is a limitation 
of Study I. Although the data were collected 
online with the data management system, we 
cannot exclude the possibility of some false 
recordings related to patient care, movement, 
or signal artefacts. All data was checked be-
fore analysis and outliers were eliminated and 
bias seems unlikely because of the substantial 
number of recorded values. In addition we did 
not record the fluid balance, which could have 
been informative concerning CVP. 
A limitation of Study II is the small sample 
size. The patient group, however, was homoge-
neous with regard to the severity and timing 
of septic shock. In the correlation analysis, 
samples of one patient are pooled from several 
time points, which may have affected the re-
sults. 
Limitations of the Study III were that we 
were able to include only part of the Finnsepsis 
study patients. These patients, however, did not 
differ from patients without consent for blood 
samples. Because of the nature of the study, 
we were not able to control the hemodynamic 
treatment, and we did not have any load inde-
pendent measurements about cardiac function 
during sepsis. In addition, the amount of vol-
ume resuscitation before blood samples is not 
definite and is missing for part of the patients. 
The sample in Study IV was relatively 
small, but with the tight inclusion criteria the 
study group is a uniform group of patients who 
most probably would have had a benefit of ag-
gressive early treatment. As a limitation, we 
did not assess the patient’s status on arrival to 
the ED and, therefore, timing of some relevant 
treatments, such as fluids, were not recorded 
exactly during the ED stay. In addition, we 
only included patients that had been admitted 
to the ICU because of septic shock and it is 
possible that some patients that had avoided 
ICU admission, because of proper EGDT ther-
apy in the ED, may not have been included. We 
did not assess the clinical situation in the ED, 
which may have affected treatment decisions.
Hemodynamic variables in outcome prediction 
and as treatment targets in septic shock
Our results suggest that during standard treat-
ment the most important hemodynamic vari-
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ables predicting the 30-day outcome in septic 
shock are MAP and lactate for the first six 
hours and MAP, SvO2, and CVP for the first 48 
hours. The best predictive threshold level for 
mortality was MAP of 65 mmHg and SvO2 of 
70  % supporting the current guidelines. 
Poeze et al. studied regional and global he-
modynamic variables as an outcome indicator 
in 28 patients with septic shock (Poeze et al. 
2005). They found that upon admission no 
variable was superior to others as a predictor 
of outcome, but after stabilization the variables 
of splanchnic function were better predictors, 
than common pressure- or volume- related 
variables. They used only single MAP, CVP, 
and Paop measurements before and after resus-
citation treatment, however, and they did not 
measured SvO2 at all. Most studies report he-
modynamic variables as a single measurement 
or as a mean of a couple of values. In septic 
shock this approach may be misleading since 
rapid changes in hemodynamics occur due to 
the disease and the treatment. We used param-
eters derived from the continuous monitoring 
of MAP and SvO2, allowing better exploration 
of these parameters cumulatively over time. 
We also took into account both the duration 
and severity of hypotension and hypoperfu-
sion. We did not find hypotension time or area 
more informative than the mean MAP over six 
hours or 48 hours, although the highest AUC 
value was found for hypotension area under 
65 mmHg (AUC 0.853, 95  % CI 0.772–0.934). 
The hyperperfusion area of SvO2 under 70  % 
was more predictive than the mean value of the 
continuous SvO2 measurements over 48 h. 
One interesting finding was the predictive 
impact of high CVP. One reason for high CVP 
could be a volume over-loading. A recent ob-
servational pan-European study reported that 
a positive fluid balance was among the stron-
gest prognostic factors for death (Vincent et al. 
2006). In a prospective randomised study of 
ARDS the conservative strategy of fluid man-
agement improved lung function and short-
ened the duration of mechanical ventilation 
and intensive care stay patients (Wiedemann 
et al. 2006).
Based on our data, however, it is not pos-
sible to assess whether more aggressive treat-
ment targeting to higher MAP and SvO2 im-
proves survival. In septic shock observational 
studies have shown a higher CI, higher SvO2, 
and higher oxygen delivery and consumption 
in survivors. Several goal-directed studies 
targeting at survivors’ supranormal hemody-
namic pattern have failed to show benefit in 
sepsis. Those who actually reach the targets 
had a better outcome, however, indicating the 
crucial importance of hemodynamic response 
on survival. This favorable response may only 
be a marker of a less severe disease itself, not of 
benefit of treatment. We did not find that dose 
of norepinephrine predict survival indepen-
dently which support the importance of dis-
ease severity over treatment. The MAP was a 
predictive sign irrespective of NA dose. Several 
opposite findings exist, however. Nitric oxide 
synthase inhibitor, NG-methyl-L-arginine hy-
drochloride, increased mortality although the 
perfusion pressure was better maintained with 
the treatment (Lopez et al. 2004). 
The trial by Rivers et al. found that the early 
goal-directed therapy targeting to MAP over 
65 mmHg, CVP 8 to 12 mmHg and ScvO2 over 
70  % during the first six hours in the emergen-
cy department resulted in a significant reduc-
tion in mortality in septic patients (Rivers et al. 
2001). The meta-analysis on trials that describe 
the hemodynamic goals in acute, critically ill 
patients revealed statistically significant mor-
tality reductions when patients with acute criti-
cal illness were treated early to achieve optimal 
goals before the development of organ failure 
(Kern and Shoemaker 2002). It seems that the 
time course of sepsis is of outstanding impor-
tance when the hemodynamics of the patient 
and hemodynamic treatment is evaluated.
Clinical importance of NT-proBNP in outcome 
prediction of septic shock
NT-proBNP is commonly elevated in pa-
tients with severe sepsis and septic shock. 
NT-proBNP at 72 hrs in the ICU was an inde-
pendent predictor of hospital and ICU mortal-
ity. According to our results, the acute cardiac 
load contributes to the NTproBNP values at 
admission, but renal failure is the main con-
founding factor later. 
Few studies, with a relatively small number 
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of patients and selected populations, have in-
vestigated the predictive power of NPs in se-
vere sepsis (Brueckmann et al. 2005; Charpen-
tier et al. 2004;Hoffmann et al. 2005; Roch et 
al. 2005). In agreement with our results, these 
earlier studies also found significantly elevated 
levels of NPs in non-survivors compared to 
survivors. A very recent study could not verify 
the prognostic value of BNP in 40 patients with 
severe sepsis and septic shock, but there was an 
inadequately low number of non-survivors for 
mortality analysis (McLean et al. 2007).
Factors that increase the wall stress of myo-
cardium lead to increased production of natri-
uretic peptides. In our patients these factors 
could be septic myocardial depression, volume 
overloading, or excessive use of vasopressors. 
Several studies have found a correlation be-
tween septic myocardial depression and natri-
uretic peptides (Charpentier et al. 2004, Roch 
et al. 2005). We did not found any association 
between CI and NT-proBNP. This is not sur-
prising because CI is a load-dependent mea-
surement and after fluid loading elevated CI is 
commonly seen in septic shock despite of the 
myocardial depression. The low CI as well may 
be a sign of hypovolemia, not myocardial de-
pression. The dose of NE correlated to the NT-
proBNP values in univariate analysis but this 
was not seen in linear regression analysis any 
more. Elevated Paop had an independent ef-
fect on NT-proBNP levels on the first day. The 
reasons for this could be the volume loading, 
myocardial depression, or both, Unfortunately 
we were not able to register the amount of vol-
ume loading trustworthly. In addition, patients 
with septic myocardial depression generally 
need much volume loading for hemodynamic 
support (Charpentier at al. 2004).
We showed that NT-proBNP predicts mor-
tality in severe sepsis and septic shock. Its us-
age as a biomarker in sepsis is promising. More 
studies, however, are needed on the physiolog-
ic implications of NPs, influence of treatment 
on NPs, confounding factors, optimal time 
of analysis, optimal cut-off points in different 
assay preparations, and activation of the neu-
roendocrine system in sepsis as a whole, before 
we are able to use these data for treatment deci-
sions or for outcome prediction.
Agreement of SvO2 and ScvO2
Study II demonstrated that during the first day 
in ICU, the average difference between ScvO2 
and SvO2 values was 4  %, but the individual 
differences varied from 8  % to 17  % and thus 
ScvO2 and SvO2 are neither equal nor inter-
changeable. 
The clinical utility of ScvO2 is documented 
in the early setting of septic shock and whether 
it equals SvO2 in this phase is less relevant. It 
is more relevant to understand the pathophysi-
ological differences of these two measurements 
later in the ICU settings and the fact that the 
results about treatment of early sepsis can not 
be extrapolated to patients who are treated af-
ter the resuscitation period in the ICUs. 
In study I we showed that SvO2 values below 
70  % increased the risk of mortality in septic 
shock. According to the data from Study II, 
16  % of SvO2 values were below 70  %, while 
ScvO2 was above 70  %. If we then assume that 
SvO2 over 65  % and ScvO2 over 70  % are clini-
cally acceptable, treatment decisions would still 
have been different after 14  % of the measure-
ments (either SvO2 below 65  % while ScvO2 
over 70  % or SvO2 over 65  % while ScvO2 be-
low 70  %). 
In the study conducted by Reinhart et al., 
evaluating critically ill patients during an av-
erage of 56 hours with the continuous mea-
surement of ScvO2, over 87  % of the values of 
nonsurvivors and 95  % of those of survivors 
were over 70  % (Reinhart et al. 2004). This may 
suggest that a ScvO2 of 70  % as a treatment goal 
in septic shock after the resuscitation period is 
insensitive for the detection of tissue oxygen 
demand. In addition, nearly 20  % of abrupt 
changes over 10  % of SvO2 cannot be detected 
with ScvO2 in severe sepsis or septic shock 
(Martin et al. 1992)
Role of early treatment  
in septic shock in Finland
The adoption of the EGDT concept and Sep-
sis Resuscitation Bundle was unsatisfactory in 
Finnish hospitals in 2004–2005. Moreover, the 
failure in rapid diagnosis and start of appropri-
ate treatment reflected on mortality. Delayed 
start of antibiotics was the most significant 
separate early treatment variable influencing 
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the excess of deaths. 
Study IV was conducted without any local 
protocol implementation and before national 
guidelines were published in Finland. Mortal-
ity rates of the compliant and non-compliant 
group in our study were comparable to the 
mortality reduction that has been reported in 
studies comparing outcomes before and after 
sepsis protocol implementation (Micek et al. 
2006; Otero et al. 2006; Shapiro et al. 2006; 
Trzeciak et al. 2006). These before and after 
comparisons have all been done in single hos-
pitals mostly using retrospective control pa-
tients and different protocols. In real life, even 
after active an protocol implementation pro-
cess, patients are treated differently. A recent 
work by Ngyen et al. showed that during the 
two years follow-up, along with the active pro-
tocol implementation, only 77 of 330 eligible 
patients completed the early treatment bundle, 
although compliance increased with time. The 
hospital mortality of the compliant and non-
compliant group was 21  % and 40  %, which 
was comparable to our results. 
Only a few studies besides ours have evalu-
ated which separate components are most im-
portant for a better outcome. In a prospective 
study by Mizek et al. (Micek et al. 2006), not 
achieving 20 mL/kg intravenous fluid admin-
istration before vasopressors in the ED, was 
independently associated with hospital mor-
tality. In a study by Ngyen et al., the start of 
antibiotics within four hours, monitoring of 
lactate clearance and completing the whole 
EGDT or bundle protocol were associated with 
the better outcome. In our study the delay in 
antimicrobial therapy was associated with a 
worse outcome. Kumar et al. showed that after 
detection of hypotension, the mortality in-
creased for every single hour that the adequate 
antimicrobial treatment was delayed (Kumar 
et al. 2006). Also, in a prospective study, by 
Garnacho-Montero et al., of 224 patients with 
sepsis (of which 114 in septic shock), a risk for 
in-hospital mortality increased by 9  % for ev-
ery hour of delay of the administration of the 
correct antibiotic (Garnacho-Montero et al. 
2006).
We also found that EGDT procedures were 
only seldom performed in the ED and thus the 
early treatment was more often unsatisfactory 
when the transfer was delayed from the ED to 
the ICU.
Clinical implications and future perspectives
The most relevant finding concerning ev-
eryday clinical practice was the reality of the 
early treatment of septic shock in Finland and 
especially the importance of the early start of 
antimicrobial treatment in septic shock. The 
importance of time delay is well understood 
in the treatment of myocardial infarction or 
stroke, but based on our results, is still un-
derestimated in septic shock. International 
guidelines and clinical studies are not enough 
for adequate implication of new treatment pro-
tocol especially when multidiscipline skills are 
needed. The national guidelines and organized 
local protocol implementation and education 
across the clinical boundaries may be manda-
tory for a better outcome in severe sepsis and 
septic shock. While the whole protocol may be 
difficult to realize, even small changes like the 
earlier start of antibiotic treatment may lead to 
better results.
Another implication for clinical practice is 
that ScvO2 can not be used as a substitute for 
SvO2 in septic shock as estimation of global 
perfusion. The ScvO2 and SvO2 vary highly 
even with comparable vasoactive treatment 
and thus SvO2 is not estimated on the basis of 
ScvO2. The usefulness of SvO2 itself in guiding 
the treatment in septic shock, however, needs 
to be re-evaluated in a randomized trial using 
goal-oriented therapy and continuous mea-
surements.
In septic shock during the first two days, 
the routinely monitored variables MAP, SvO2, 
CVP, and lactate on arrival associate with mor-
tality. Our results support the recent guidelines 
aiming at aMAP over 65 mmHg and SvO2 over 
70  %, although we did not study hemodynamic 
parameters as treatment targets. 
The implication of the clinical use of NT-
proBNP in outcome prediction is a still con-
troversial issue. We should know more about 
the etiology of NT-proBNP elevation in septic 
shock, whether the disease itself or aggressive 
treatment leads to the excessive elevation. Also 
the impact of the elevation of BNP or ANP on 
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the hemodynamic course of shock needs fur-
ther studies. 
Severe sepsis and septic shock still carries 
a high mortality even though studies in 20th 
century have shown that reduction in mortal-
ity is possible. Sepsis has been studied exten-
sively in recent years. One of the most impor-
tant issues that has been understood, is the 
relevance of timing concerning the outcome. 
The timing should be taken into account in fu-
ture trials because it is obvious that the whole 
pathophysiologic entity in septic shock is dif-
ferent in early sepsis, before resuscitation treat-
ment, and later if the shock persists. One major 
problem concerning the outcome studies is the 
highly complicated course of illness when all 
confounders can hardly be controlled, even 
though the single treatment strategy could be 
of benefit. Extremely large study populations 
would be needed to prove the benefit. On the 
other hand the heterogenity of patients make 
the interpretation of the results difficult in the 
large study populations. For example, the ef-
ficacy of drotrecogin alfa or corticosteroids 
depends on the severity of the illness even if all 
patients have septic shock by definition (An-
nane et al.2002, Bernard et al. 2001, Abraham 
et al. 2005). Some treatment that does not show 
a significant benefit in trials may still help a 
small subgroup of patients with special charac-
teristics (Deans et al. 2007). That denotes that 
the results of the studies about a mixed critical 
illness population should be interpretated with 
caution. 
The clinical picture vary a lot in septic shock. 
Some may have a refractory shock unrespon-
sive to vasopressors, some an extremely in-
creased permeability and pulmonary oedema, 
and some may show a fulminant myocardial 
depression. More individually targeted treat-
ment for special hemodynamic characteristics 
might be needed in septic shock in future. The 
one of the most important study subjects in 
future is the microcirculation. The ongoing 
disturbations of microcirculation after the first 
resuscitation are of great importance concern-
ing for both mortality and morbidity. While 
systemic hemodynamics can be maintained 
at the expense of impaired microcirculatory 
perfusion, it would be extremely important to 
develop new biomarkers or monitoring meth-
ods about microcirculation for everyday clini-
cal use.
In the near future, the role of vasopressin 
and its derivatives in extreme vasodilatation 
will hopefully become clearer and the studies 
focusing on the tretment options for extreme 
vessel permeability would be of great inter-
est. The unsolved problem of optimal volume 
replacement therapy and optimal monitoring 
of volume replacement needs further stud-
ies. Interesting issues are, if the treatment of 
septic myocardial dysfunction with inotropes 
improve the outcome, even in the absence of a 
global perfusion deficit, and what is the optimal 
trigger for starting the inotropic treatment. 
The one intriguing question is, which are the 
most important hemodynamic treatment tar-
gets and can the outcome be improved with a 
specific goal-directed hemodynamic treatment 
even after resuscitation period. It might be a 
delusion, however, to imagine that a similarly 
targeted hemodynamic treatment would ever 
be a solution in a complex and highly variable 
hemodynamic course in septic shock.
At this time no a quick and accurate sero-
logic tests or biomarkers for clinical use exist. 
Hopefully some marker in future will provide 
a simple bedside test that will help in earlier 
diagnosis and treatment decisions in sepsis. 
Our findings on NT-proBNP might inspire 
new studies on the role of natriuretic peptides 
in treatment decisions concerning inotropes or 
volume loading. It would be exciting to know, 
if the extreme elevation of NPs is already seen 
from the first beginning of septic shock or is it 
atleast partly induced by aggressive treatment 
and what is the relevance of NPs in septic va-
sodilatation. 
A new century had shed light on the devas-
tating course of septic shock. While the active 
investigation of the complex pathogenesis and 
development of new innovative therapies con-
tinue, there is a one thing, which we allready 
know. That is the importance of the early treat-
ment. If the first golden hours, the window of 
opportunity, are missed, the salvation of the 
patient is much more difficult. We can not ig-
nore that.
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8 CONCLUSIONS
Based on the results of these studies the following conclusions can be 
drawn:
1. Low average mean arterial pressure, mixed oxygen saturation values 
below 70  % and high average central venous pressure during the first 48 
hours of treatment, are associated with mortality in septic shock. The 
best discriminative threshold values are 65 mmHg for MAP and 70  % 
for SvO2.
2. Central venous oxygen saturation and mixed oxygen saturation are not 
equal or interchangeable in hemodynamic evaluation of patient with 
septic shock in the ICU.
3. The N-terminal pro-brain natriuretic peptide is commonly elevated 
in severe sepsis or septic shock and it is an independent predictor of 
survival in day three in the ICU. 
4. Inappropriate early treatment of septic shock and especially the delay 
in the start of antibiotics impair the prognosis of septic shock. Early 
treatment of septic shock is not optimal in Finland.
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